<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Nutr.</journal-id>
<journal-title>Frontiers in Nutrition</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Nutr.</abbrev-journal-title>
<issn pub-type="epub">2296-861X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnut.2024.1266690</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Nutrition</subject>
<subj-group>
<subject>Mini Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Ketogenic therapy towards precision medicine for brain diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name>
<surname>Liu</surname>
<given-names>Yang</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1800196/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Fan</surname>
<given-names>Linlin</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2654282/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Yang</surname>
<given-names>Haoying</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1848422/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Wang</surname>
<given-names>Danli</given-names>
</name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2646331/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Runhan</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1848068/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Shan</surname>
<given-names>Tikun</given-names>
</name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="corresp" rid="c002"><sup>&#x002A;</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Xia</surname>
<given-names>Xue</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<xref ref-type="corresp" rid="c003"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1244842/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Translational Medicine Center, Huaihe Hospital of Henan University, Henan University</institution>, <addr-line>Kaifeng</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Henan Key Laboratory of Brain Targeted Bio-nanomedicine, School of Life Sciences, Henan University</institution>, <addr-line>Kaifeng</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Zhoushan People&#x2019;s Hospital</institution>, <addr-line>Zhoushan</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>Neurosurgery Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country></aff>
<aff id="aff5"><sup>5</sup><institution>School of Environmental and Life Sciences, College of Engineering, Science and Environment, University of Newcastle</institution>, <addr-line>Callaghan, NSW</addr-line>, <country>Australia</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0002">
<p>Edited by: Sunmin Park, Hoseo University, Republic of Korea</p>
</fn>
<fn fn-type="edited-by" id="fn0003">
<p>Reviewed by: Zhenwei Cui, Zhengzhou University, China</p>
<p>Sergei V. Fedorovich, Belarusian State University, Belarus</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Yang Liu, <email>liuyang.jcbi@henu.edu.cn</email></corresp>
<corresp id="c002">Tikun Shan, <email>shantikun@petalmail.com</email></corresp>
<corresp id="c003">Xue Xia, <email>x.xia@henu.edu.cn</email></corresp>
<fn fn-type="equal" id="fn0001">
<p><sup>&#x2020;</sup>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>02</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>11</volume>
<elocation-id>1266690</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>07</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>01</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2024 Liu, Fan, Yang, Wang, Liu, Shan and Xia.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Liu, Fan, Yang, Wang, Liu, Shan and Xia</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Precision nutrition and nutrigenomics are emerging in the development of therapies for multiple diseases. The ketogenic diet (KD) is the most widely used clinical diet, providing high fat, low carbohydrate, and adequate protein. KD produces ketones and alters the metabolism of patients. Growing evidence suggests that KD has therapeutic effects in a wide range of neuronal diseases including epilepsy, neurodegeneration, cancer, and metabolic disorders. Although KD is considered to be a low-side-effect diet treatment, its therapeutic mechanism has not yet been fully elucidated. Also, its induced keto-response among different populations has not been elucidated. Understanding the ketone metabolism in health and disease is critical for the development of KD-associated therapeutics and synergistic therapy under any physiological background. Here, we review the current advances and known heterogeneity of the KD response and discuss the prospects for KD therapy from a precision nutrition perspective.</p>
</abstract>
<kwd-group>
<kwd>ketogenic diet</kwd>
<kwd>precision medicine</kwd>
<kwd>brain disease</kwd>
<kwd>nutrigenomics</kwd>
<kwd>neural disease</kwd>
</kwd-group>
<counts>
<fig-count count="2"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="129"/>
<page-count count="10"/>
<word-count count="9520"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Nutrigenomics</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p>The ketogenic diet (KD) is a high-fat diet that also restricts carbohydrates, and triggers the body&#x2019;s production of ketones for energy use. The change in these macronutrient ratios from the original diet to KD rewires human energy metabolism to utilize ketones, which are derived from fatty acids, as an energy source instead of glucose (<xref ref-type="bibr" rid="ref1">1</xref>). KD is one of the most widely used clinical diets for disease treatment and has become an established non-pharmacological intervention for many neurological diseases. As early as 1921, Drs. Rollin Turner Woodyatt and Russell Morse Wilder at the Mayo Clinic coined the term &#x201C;ketogenic diet&#x201D; and proposed that dietary ketones were as effective as fasting for the management of epilepsy but with long-lasting results (<xref ref-type="bibr" rid="ref2">2</xref>). KD has therefore been intensively studied for the treatment of epilepsy. After the discovery of diphenylhydantoin as a chemical drug for seizures in 1938, the attention of physicians and researchers shifted from KD to the new anti-epileptic drug. At that time, interest in KD for the treatment of this disease decreased and did not come to people&#x2019;s attention again until the 1990s (<xref ref-type="bibr" rid="ref2">2</xref>, <xref ref-type="bibr" rid="ref3">3</xref>), when its therapeutic effects were gradually found to be effective in a wide range of diseases and more therapeutic potentials of KD were proposed. To clinically apply KD as a nutritional aid, standardization and specialization are extremely important. The &#x201C;International Ketogenic Diet Expert Consensus Guidelines&#x201D; were published in 2009 and have been frequently updated since then. Key milestones in KD therapy are summarized in <xref ref-type="fig" rid="fig1">Figure 1</xref>. In this review, our search strategy was designed by a multi-disciplinary team with backgrounds in nutrition, pharmacy, neurology, and clinical medicine; the goal was to ensure coverage of a wide range of issues and literature including and emphasizing the most classic publications screened by high citations or published by leading scholars. The most recent research was screened based on recent 5-year findings. We conducted an initial review via Google Scholar and PubMed and screened the available titles and abstracts. A further detailed review included highly relevant literature and cited references. Documents with less relevance were retrieved for further review.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>History and classification of the KD therapy. <bold>(A)</bold> Highlighted events in the development of ketogenic diet therapy. <bold>(B)</bold> Mechanistic hypothesis for KD treatments. <bold>(C)</bold> Structure of ketones, Acetoacetate (AcAc), &#x03B2;-hydroxybutyrate (BHB), and acetone. <bold>(D)</bold> Nutrient composition for the main KD variants. RCT, randomized clinical trial; CKD, classic ketogenic diet; MCTD, medium-chain triglyceride diet; HDACs, histone deacetylases.</p>
</caption>
<graphic xlink:href="fnut-11-1266690-g001.tif"/>
</fig>
</sec>
<sec id="sec2">
<label>2</label>
<title>Heterogeneity of KD therapy and the need for precision nutrition</title>
<p>The physiological function of KD is mainly triggered by ketones. Acetoacetate (AcAc), &#x03B2;-hydroxybutyrate (BHB), and acetone are collectively known as ketones or ketone bodies (<xref ref-type="bibr" rid="ref4">4</xref>) (<xref ref-type="fig" rid="fig1">Figure 1</xref>), which can be generated from a series of biochemical reactions associated with fatty acid oxidation and are key mediators of KD therapy. Both BHB and AcAc are metabolizable and can be used as energy sources in different tissues. Ketogenesis is the term that describes the chemical reaction process that generates ketones. Fatty acid oxidation activated by starvation or diabetes triggers high levels of ketone production in the liver. This ketone-generating metabolic process is known as ketosis, which burns fat for fuel when the body lacks sufficient carbohydrates as an energy source.</p>
<p>To achieve greater flexibility and adherence to metabolic switch with KD, different formulations have been developed over the past decades, with four main KD variants now widely accepted by researchers and physicians: Classic KD (CKD), Modified Atkins Diet (MAD), Medium Chain Triglyceride Diet (MCT), and Low Glycemic Index Therapy (LGIT) (<xref ref-type="bibr" rid="ref5">5</xref>). Classic KD is a rigid diet in which fat provides 90% of calories and its main source is Long-Chain Triglycerides (LCT) from food intake (<xref ref-type="bibr" rid="ref1">1</xref>). Classic KD is widely used in clinical practice and is recommended for children under the age of two (<xref ref-type="bibr" rid="ref5">5</xref>). For adolescents and adults, the majority (72%) of the consensus group prefers MAD or LGIT, mainly due to better adherence (<xref ref-type="bibr" rid="ref5">5</xref>). MAD is a low-glycemic index (GI &#x003C; 50) diet; it does not restrict calories and fluids due to its high-fat content and supplies more protein than classic KD. MAD is increasingly used in adults due to its better availability and tolerability (<xref ref-type="bibr" rid="ref6">6</xref>). Its formulation features approximately 65% fat, 25% protein, and 10% carbohydrates (<xref ref-type="bibr" rid="ref7">7</xref>). Another low-GI formula, LGIT, is based on a macronutrient composition of 60% fat, 30% protein, and 10% carbohydrates (<xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref8">8</xref>). Studies have demonstrated that LIGT has a good seizure control effect and fewer side effects, which makes it an effective option for managing seizures associated with Angelman syndrome (<xref ref-type="bibr" rid="ref9">9</xref>). However, LGIT is not recommended for the treatment of glucose transporter-1 deficiency syndrome (Glut1DS) or pyruvate dehydrogenase deficiency (PDHD) due to inadequate ketosis induction (<xref ref-type="bibr" rid="ref5">5</xref>). Meanwhile MAD has shown good results in the treatment of Glut1DS (<xref ref-type="bibr" rid="ref8">8</xref>). MCT is primarily composed of up to 60% medium-chain fatty acids from coconut or palm kernel oil used as a dietary supplement. MCT provides an option for people with carnitine deficiency, as carnitine is necessary for the processing of long-chain fatty acids provided by classic KD and it supplies more carbohydrates and protein for better compliance (<xref ref-type="bibr" rid="ref10">10</xref>). It is also important to consider certain limitations when initiating MCT, as it may result in adverse effects such as diarrhea, nausea, and vomiting. Notably, the combination of MCT and valproic acid has been reported to be associated with liver failure; therefore, patients taking valproic acid should avoid MCT (<xref ref-type="bibr" rid="ref11">11</xref>).</p>
<p>It is noteworthy that different types of KDs may have distinct effects on patient outcomes. A meta-analysis reviewed 12 studies that used CKD, MAD, and a combination of CKD and MCT for the treatment of anti-epileptic drug-resistant epilepsy in adults. Data from 270 patients showed that CKD had a response rate of 52%, while MAD had a response rate of 34%, suggesting that CKD may be more effective in some cases. However, compliance is lower with CKD (38%) compared to MAD (56%) in adult patients (<xref ref-type="bibr" rid="ref12">12</xref>).</p>
<p>This evidence demonstrates wide variation in KD formula selections and corresponding treatment outcomes, which suggests that the selection of a specific KD treatment for patients should be based on the patient&#x2019;s circumstances, and individual family genetic background, as well as the expertise guiding patient&#x2019;s adherance. This is crucial to achieving optimized therapeutic efficacy and minimizing potential side effects. In addition, as a standard treatment, KD should be closely monitored and regulated to ensure its efficacy and promote dietary adherence. Currently, urine dipsticks (<xref ref-type="bibr" rid="ref4">4</xref>), blood parameters, and breath sensors can be applied so as to monitor ketosis in clinics, and these points highlight the need for precision nutrition in clinical KD treatments.</p>
</sec>
<sec id="sec3">
<label>3</label>
<title>Physiological benefits and therapeutic potential of the ketogenic diet in the nervous system</title>
<p>There is a consensus that an animal fat-centered diet contributed significantly to the evolution of a larger human brain (<xref ref-type="bibr" rid="ref13">13</xref>). Hunting, rather than scavenging, allows humans to consume more energy-intense fatty meats, thus allowing more free energy to be redirected to fuel the brain (<xref ref-type="bibr" rid="ref14">14</xref>). Ketosis may be the result of human evolution and may be strongly tied to a time when food scarcity occurred the majority of the time. The human body evolves to better utilize and conserve energy under such living conditions (<xref ref-type="bibr" rid="ref15">15</xref>). Starvation results in global shifts in the body&#x2019;s circulating metabolites. In particular, ketone bodies act as a substitute for glucose in providing energy to the brain. Specifically, the concentration of &#x03B2;-OHB can increase 13-fold when the human body is subjected to prolonged starvation. The level of ketones, which contribute to cerebral metabolism, also increases profoundly. The source of such ketone synthesis in the liver, when the body is under glucose starvation, is smart from the point of view that fatty acids themselves, originating from the body&#x2019;s fat reserves, cannot cross the blood&#x2013;brain barrier and thus satisfy the brain&#x2019;s energy needs (<xref ref-type="bibr" rid="ref16">16</xref>, <xref ref-type="bibr" rid="ref17">17</xref>).</p>
<sec id="sec4">
<label>3.1</label>
<title>Essential role of ketone metabolism in the neonatal brain</title>
<p>Compared to the adult brain, the brain of neonates utilizes ketones and lactate to a much greater extent than glucose (<xref ref-type="bibr" rid="ref18">18</xref>). In neonatal rats, BHB and AcAc are preferred to glucose as they are substrates for the synthesis of phospholipids and sphingolipids, which are required for brain growth and myelination (<xref ref-type="bibr" rid="ref19">19</xref>, <xref ref-type="bibr" rid="ref20">20</xref>). To date, the ketone body content of the human neonatal brain is reported to be 40-fold higher than that of the adult brain (<xref ref-type="bibr" rid="ref21">21</xref>). Ketone bodies are a necessary energy source for fetal neurodevelopment, and monocarboxylate transporters are considered responsible for ketone bodies across the blood&#x2013;brain barrier (<xref ref-type="bibr" rid="ref22">22</xref>). Ketones are present in the blood of neonates and pregnant women, and even a few days after birth, human infants remain in ketosis (<xref ref-type="bibr" rid="ref23">23</xref>). With the capacity to freely cross the placenta, exogenous ketone treatment has been reported to preserve cerebral energy metabolism, ameliorate brain damage, and display effective neuroprotective potency during neonatal hypoxia-ischemia (<xref ref-type="bibr" rid="ref24">24</xref>, <xref ref-type="bibr" rid="ref25">25</xref>). Data also suggest that 5&#x2009;mM BHB in the circulation may improve the survival rate of brain cells (<xref ref-type="bibr" rid="ref26">26</xref>). In a rodent model of neonatal hypoxia, induction of ketosis was reported to reduce brain damage after exposure to 3&#x2009;h of hypoxia (<xref ref-type="bibr" rid="ref27">27</xref>). Collectively, this evidence suggests a protective role for ketone bodies in the neonatal brain under extreme conditions.</p>
</sec>
<sec id="sec5">
<label>3.2</label>
<title>Benefits of a ketogenic diet in the adult brain</title>
<p>Ketones also contribute uniquely to the maturation of the nervous system by promoting myelin formation. Studies have indicated that KD is useful in adult remyelination, during which axon damage is repaired and attenuated (<xref ref-type="bibr" rid="ref28">28</xref>). The neuronal protective effects induced by KD also involved multiple pathways, such as modulation of ATP-sensitive potassium (K-ATP) channels, enhanced purinergic and GABAergic neurotransmission, increased expression of brain-derived neurotrophic factor (BDNF), attenuation of neuroinflammation, expansion of bioenergetic reserves, and stabilization of the neuronal membrane potential through improved mitochondrial function (<xref ref-type="bibr" rid="ref29">29</xref>). The benefits associated with KD have been extensively reviewed (<xref ref-type="bibr" rid="ref30">30</xref>, <xref ref-type="bibr" rid="ref31">31</xref>). As the key functional KD factor, BHB directly regulates inflammation and neurotrophic factors by inhibiting the activation of the innate immune sensor NLRP3 and inhibiting HDAC, thereby maintaining, restoring, and improving brain function (<xref ref-type="bibr" rid="ref32">32</xref>). Studies also demonstrate that ketones, which are biomarkers of the brain&#x2019;s aging response to fuel sources, increase the stability of brain networks, while decreasing glucose, affecting overall brain activity (<xref ref-type="bibr" rid="ref33">33</xref>).</p>
</sec>
<sec id="sec6">
<label>3.3</label>
<title>The potential of a ketogenic diet to improve motor neuron function</title>
<p>In the peripheral nervous system, mice fed a KD diet show increased epidermal axon density and neurite outgrowth in sensory neurons (<xref ref-type="bibr" rid="ref34">34</xref>), which implies that ketones may provide benefits to peripheral axons and sensory functional recovery. In an amyotrophic lateral sclerosis (ALS) mouse model (SOD1<sup>G93A</sup>), the administration of KD was able to promote ATP synthesis by bypassing the inhibited complex I in the mitochondrial respiratory chain, increasing mitochondrial energy production and membrane stabilization, leading to increased motor neuron survival and improved motor function compared to normally fed mice. Although human trials are still insufficient and the survival time of treated mice was not increased, researchers found both histological and functional improvement in the KD-treated ALS animal model, with higher motor neuron counts and less motor function impairment (<xref ref-type="bibr" rid="ref35">35</xref>, <xref ref-type="bibr" rid="ref36">36</xref>). In line with this, motor function also showed improvement in rodent models on KD and/or MCT diets in neurodegenerative diseases and spinal cord injury (<xref ref-type="bibr" rid="ref37">37</xref>, <xref ref-type="bibr" rid="ref38">38</xref>). Taken together, KD shows a broad spectrum of benefits to nervous system function through a variety of mechanisms.</p>
</sec>
</sec>
<sec id="sec7">
<label>4</label>
<title>Hypothetical functional mechanisms for ketogenic diet therapy</title>
<p>During diet-induced glucose deficiency, ketone bodies are generated in the liver and circulated in the bloodstream to metabolically active tissues for processing as energy substrates. In particular, BHB, in addition to its role as an energy source, also has a variety of molecular signaling and regulatory functions in a wide range of human diseases (<xref ref-type="bibr" rid="ref39">39</xref>). BHB is considered to be the main efficacy factor in KD treatment. In addition to influencing the process of oxidative metabolism, BHB also plays a direct role as an endogenous ligand of the hydroxycarboxylic acid receptor 2 (HCA2), whose activation by nutritional or pharmacological approaches could ameliorate neuroinflammation (<xref ref-type="bibr" rid="ref40">40</xref>). Moreover, ketone bodies are also important in the synaptic vesicular cycle (<xref ref-type="bibr" rid="ref41">41</xref>), KD can also affect neurotransmitter levels in the synaptic cleft and increase GABA levels in addition to altering glutamate metabolism (<xref ref-type="bibr" rid="ref42">42</xref>). BHB may well play its neuroprotective role through the above mechanisms.</p>
<sec id="sec8">
<label>4.1</label>
<title>Epigenetic regulation</title>
<p>BHB has been reported as a Class I histone deacetylase (HDAC) inhibitor and an endogenous neuroprotective epigenetic modifier (<xref ref-type="bibr" rid="ref43">43</xref>). As an HDAC inhibitor, BHB is involved in histone regulation through acetylation. Through local histone acetylation induction at the promoter of oxidative stress resistance genes such as forkhead box O3 (Foxo3a) and metallothionein2 (Mt2) (<xref ref-type="bibr" rid="ref44">44</xref>), BHB has bridged the connection between metabolic and epigenetic modifications and gene expression. Studies have also shown a more direct epigenetic effect of BHB, defining a novel histone modification as &#x03B2;-hydroxybutyrylation at H3K9 (<xref ref-type="bibr" rid="ref45">45</xref>). KD can also reportedly increase the levels of lysine acetylation and p53 acetylation, which are some of the most important cell cycle regulators and tumor suppressors (<xref ref-type="bibr" rid="ref46">46</xref>).</p>
</sec>
<sec id="sec9">
<label>4.2</label>
<title>Gut microbiome</title>
<p>Gut microbes are also known to be involved in the development of many diseases. The dietary influence of KD on gut microbes is easily presumed. One study reported that KD significantly reduced the diversity of the intestinal flora, but at the same time, <italic>Parabacteroides</italic> and <italic>Akkermansia muciniphila</italic> increased during KD intake (<xref ref-type="bibr" rid="ref47">47</xref>). Researchers found that a shift in the microbiome led to changes in the intestinal metabolome of the colon, resulting in a decrease in gamma-glutamyl amino acids, which may be beneficial for seizure protection (<xref ref-type="bibr" rid="ref48">48</xref>). The influence of the gut microbiome on disease is still largely unknown, and the underlying mechanism requires further investigation. Moreover, significant changes in microbial communities combined with different dietary compositions may drive different molecular inputs to neuroendocrine signaling pathways, and these altered inputs (e.g., short-chain fatty acid response) combined with changes in the gut-brain axis may drive different systemic responses at the level of hormones and gene expression (<xref ref-type="bibr" rid="ref49">49</xref>).</p>
</sec>
<sec id="sec10">
<label>4.3</label>
<title>Oxidative stress and inflammatory pathways</title>
<p>Disturbances in mitochondrial energy metabolism and reactive oxygen species (ROS) production are key players in many diseases. KD significantly affects mitochondrial energy metabolism. For instance, studies have shown that KD increases the antioxidant glutathione levels, and activates the transcription factor Nrf2 (nuclear factor erythroid-2 related factor) detoxification pathway (<xref ref-type="bibr" rid="ref50">50</xref>, <xref ref-type="bibr" rid="ref51">51</xref>). Both glutathione and Nrf2 are crucial for balancing ROS levels (<xref ref-type="bibr" rid="ref52">52</xref>). Furthermore, in a glioma mouse model, KD induces anti-tumor effects and reduces ROS production in tumor cells by regulating ROS-associated gene expression (<xref ref-type="bibr" rid="ref53">53</xref>).</p>
<p>Moreover, KD showed a powerful anti-inflammatory effect. Ketones, especially BHB, have been reported to reduce cardiac inflammation, decrease the development of heart failure (<xref ref-type="bibr" rid="ref54">54</xref>), and ameliorate the inflammation after spinal cord injury (<xref ref-type="bibr" rid="ref55">55</xref>). KD also has a promising role in inhibiting NOD-like receptor protein 3 (NLRP3) inflammasome assembly, reducing oxidative damage, and attenuating inflammatory mediators produced by infiltrating macrophages (<xref ref-type="bibr" rid="ref56">56</xref>). Although evidence has been found and several hypotheses have been proposed, the clear mechanism for the benefit of KD still needs to be further explored.</p>
</sec>
</sec>
<sec id="sec11">
<label>5</label>
<title>Ketogenic therapy for precision medicine</title>
<sec id="sec12">
<label>5.1</label>
<title>Public need for precision nutrition and nutrigenomics</title>
<p>Precision medicine is a term that describes new therapeutic strategies with more precise targeting, focusing on subgroups of diseases with individual backgrounds, and is the new trend for a broad spectrum of disease treatment (<xref ref-type="bibr" rid="ref57">57</xref>). The ultimate aim of precision medicine is to maximize the outcome by individualizing a broad range of patient features, including genome profiling, drug response, disease development period, physiological states, and causal inference. Formalized precision medicine treatment consists of a series of decision-making points with recommended actions, such as drug and dose selection, timing of administration, specific dietary or exercise recommendations, and other aspects of treatment that can be made following up-to-date patient information (<xref ref-type="bibr" rid="ref58">58</xref>).</p>
<p>Despite clear evidence of the impact of nutrients on health, diet as an environmental exposure is not fully highlighted in clinical practice and research. Recently, there has been an emerging awareness of &#x201C;precision nutrition,&#x201D; and more pieces of evidence have concluded that nutrient intake affects therapeutic outcomes (<xref ref-type="bibr" rid="ref59">59</xref>). Thus more precision nutrition is being proposed to replace or augment drugs to some extent (<xref ref-type="bibr" rid="ref60">60</xref>). The importance of nutrition to individual health makes nutrigenomics emerge as a hot discipline. Nutrigenomics investigates the impact of diet/nutrition on gene expression at the epigenomic, transcriptomic, proteomic, metabolomic, and microbiome levels (<xref ref-type="bibr" rid="ref61">61</xref>). Conversely, the discipline of nutrigenomics is the study of how genes affect the body&#x2019;s response to food (<xref ref-type="bibr" rid="ref62">62</xref>). All of these new disciplines aim to clarify the interaction of health, genes, and diet. Heterogeneity in patient-made precision nutrition and nutrigenomics is extremely important in KD therapy (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>The need for precision medicine and precision nutrition in disease therapy. The emerging understanding of precision nutrition and nutrigenomics enables a more focused study of ketone-triggered metabolic and epigenetic crosstalk and keto-drug interactions.</p>
</caption>
<graphic xlink:href="fnut-11-1266690-g002.tif"/>
</fig>
</sec>
<sec id="sec13">
<label>5.2</label>
<title>The ketogenic diet is beneficial for neuronal diseases and could be greatly influenced by precision medicine</title>
<p>KD has been recommended for the treatment of certain epileptic and genetic syndromes including Dravet syndrome (<xref ref-type="bibr" rid="ref63">63</xref>), myoclonic-atonic seizures (Doose syndrome) (<xref ref-type="bibr" rid="ref64">64</xref>), West syndrome (infantile spasms) (<xref ref-type="bibr" rid="ref65">65</xref>), febrile infection-related epilepsy syndrome (FIRES) (<xref ref-type="bibr" rid="ref66">66</xref>), Ohtahara syndrome (<xref ref-type="bibr" rid="ref67">67</xref>), and super-refractory focal and myoclonic status epilepticus (<xref ref-type="bibr" rid="ref68">68</xref>). Case reports have also indicated beneficial effects of KD in epileptic encephalopathies such as Lafora body disease (<xref ref-type="bibr" rid="ref69">69</xref>), early infantile epileptic encephalopathy (<xref ref-type="bibr" rid="ref70">70</xref>), Landau&#x2013;Kleffner syndrome (<xref ref-type="bibr" rid="ref71">71</xref>), subacute sclerosing panencephalitis (<xref ref-type="bibr" rid="ref72">72</xref>), adenylosuccinate lyase deficiency (<xref ref-type="bibr" rid="ref73">73</xref>), juvenile myoclonic epilepsy (<xref ref-type="bibr" rid="ref74">74</xref>), CDKL5 encephalopathy (<xref ref-type="bibr" rid="ref75">75</xref>), infantile epilepsy with migrating focal seizures (<xref ref-type="bibr" rid="ref76">76</xref>), childhood absence epilepsy (<xref ref-type="bibr" rid="ref77">77</xref>), and epileptic encephalopathy with continuous spike-and-wave during sleep (<xref ref-type="bibr" rid="ref78">78</xref>). Metabolic-to-epigenetic modulation is considered to be one of the main reasons for the therapeutic effect of KD in neurodevelopmental disorders. Although KD has shown therapeutic potential in these diseases, heterogeneity has shown varied results in KD therapy for specific disease subtypes, the clear mechanisms of which are still largely unknown. Some examples of KD therapeutic effects and exceptions are summarized below.</p>
<p><italic>Epilepsy</italic> is a common neurological disorder affecting more than 70 million people worldwide with genetic mutation as one of the leading causes (<xref ref-type="bibr" rid="ref79">79</xref>). Dietary therapy for epilepsy has a long history and was recorded in the Hippocratic Collection (<xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref80">80</xref>). KD has now become an important alternative treatment for patients with refractory epilepsy, both in children and adults (<xref ref-type="bibr" rid="ref81 ref82 ref83">81&#x2013;83</xref>). Numerous evidence have shown control of epilepsy incidence, but its cure is still extremely challenging as many refractory epilepsies are caused by genetic mutations. Some studies also concluded the failure of KD therapy. For example, patients with epilepsy with GLUT1 deficiency syndrome show non-sensitivity to KD despite adequate ketosis (<xref ref-type="bibr" rid="ref84">84</xref>). The genetic background of patients also showed differences in keto response and keto-drug interaction, making precision medicine even more important (<xref ref-type="bibr" rid="ref85">85</xref>, <xref ref-type="bibr" rid="ref86">86</xref>).</p>
<p><italic>Kabuki syndrome</italic> is an intellectual disability caused by mutations in either the <italic>KMT2D</italic> or <italic>KDM6A</italic> genes, which are involved in histone acetylation and chromatin accessibility (<xref ref-type="bibr" rid="ref87">87</xref>). In the Kmt2d<italic><sup>+/&#x03B2;Geo</sup></italic> mouse model, treatment with KD for 2&#x2009;weeks normalizes the global histone modification state corrects the neurogenesis deficiency in the granule cell layer of the dentate gyrus, and rescues the hippocampal memory defects (<xref ref-type="bibr" rid="ref88">88</xref>). These could also be achieved by administering exogenous BHB (<xref ref-type="bibr" rid="ref89">89</xref>). The mechanism behind this may be due to improved chromatin accessibility and the transcriptional regulatory network.</p>
<p><italic>Rett syndrome</italic> is most often caused by a mutation in the key epigenetic regulator gene that encodes the methyl-CpG binding protein. This mutation leads to seizures and intellectual disability (<xref ref-type="bibr" rid="ref90">90</xref>). Patients with Rett syndrome treated with KD show reduced seizures and great improvements in social and behavioral functioning (<xref ref-type="bibr" rid="ref91">91</xref>).</p>
<p><italic>Angelman syndrome</italic> is a genomic imprinting disorder associated with multiple anomalies and intellectual disability. In a mouse model of Angelman syndrome, dietary supplementation with ketones has been shown to significantly reduce the frequency of seizures and improve overall neural function including behavior, learning, and memory (<xref ref-type="bibr" rid="ref92">92</xref>). Clinical trials in children with Angelman syndrome are currently testing ketone supplementation for seizure control (<xref ref-type="bibr" rid="ref93">93</xref>).</p>
<p><italic>Psychiatric disorders and comorbidity with epilepsy</italic>. KD has also been proven to be useful in the treatment of psychiatric disorders in comorbidity with epilepsy in children and adolescents (<xref ref-type="bibr" rid="ref94">94</xref>), as well as in psychiatric disorders such as anxiety disorder (<xref ref-type="bibr" rid="ref95">95</xref>), bipolar disorder (<xref ref-type="bibr" rid="ref96">96</xref>), schizophrenia (<xref ref-type="bibr" rid="ref97">97</xref>), depression (<xref ref-type="bibr" rid="ref98">98</xref>), autism spectrum disorder and attention-deficit/hyperactivity disorder (ADHD) (<xref ref-type="bibr" rid="ref99">99</xref>). The positive outcome may be attributed to the profound impact of ketones on multiple targets, including but not limited to glutamate/GABA transmission, monoamine levels, mitochondrial function and biogenesis, neurotrophism, oxidative stress, insulin dysfunction, and inflammation, and demonstrates mood-stabilizing and antidepressant effects (<xref ref-type="bibr" rid="ref100">100</xref>).</p>
<p><italic>Alzheimer&#x2019;s disease</italic> (<italic>AD</italic>) is the most common neurodegenerative disease and the leading cause of dementia in the elderly population (<xref ref-type="bibr" rid="ref101">101</xref>). The brains of AD patients show decreased glucose uptake (<xref ref-type="bibr" rid="ref102">102</xref>). As a backup fuel for the brain, ketone bodies can cross the blood&#x2013;brain barrier, thereby improving the function of energy-starved neurons. It has been proven that KD intervention results in increased ketone utilization and brain network stabilization, which could be beneficial for the aging brain (<xref ref-type="bibr" rid="ref33">33</xref>). The mechanism behind this may be that KD alleviates energy starvation and neurotransmitter imbalance in the AD brain, as the brain metabolism of ketones can support up to 30% of glutamate and glutamine carbon (<xref ref-type="bibr" rid="ref48">48</xref>) through the glutamate decarboxylase reaction (<xref ref-type="bibr" rid="ref103">103</xref>). In animal models, 8&#x2009;months of KD feeding in middle-aged mice (8.5&#x2009;months old) improved cognition and ameliorated A&#x03B2; and tau pathology (<xref ref-type="bibr" rid="ref104">104</xref>). In the 3xTg mouse model of AD, ketone metabolism can restore TCA cycle metabolites, thereby enhancing amino acid biosynthesis and contributing to behavioral performance (<xref ref-type="bibr" rid="ref105">105</xref>). Increased ketone levels also reduce the brain&#x2019;s usage of glucose; as ketones are used preferentially over glucose by brain cells, Alzheimer&#x2019;s brains are even more efficient at taking up ketones (<xref ref-type="bibr" rid="ref106">106</xref>). KD has also shown the potential to prevent AD in high-risk populations (<xref ref-type="bibr" rid="ref107">107</xref>, <xref ref-type="bibr" rid="ref108">108</xref>). AC-1202, an oral ketogenic compound that can induce a mild state of ketosis without modifying normal diets, was developed to improve cognitive performance and resulted in significant differences in the AD Assessment Scale-Cognitive subscale scores compared to the placebo (<xref ref-type="bibr" rid="ref109">109</xref>).</p>
<p>Exceptions: It should be noted that KD shows variable outcomes for different genetic backgrounds. In this case, the oral ketogenic agent AC-1202 resulted in a statistically significant improvement in cognitive performance in patients who were <italic>APOE4</italic> negative, but not <italic>APOE4</italic> positive (<xref ref-type="bibr" rid="ref109">109</xref>). In this case, precision nutrition is extremely important in the treatment of the disease.</p>
<p><italic>Parkinson&#x2019;s disease</italic> also benefits from KD (<xref ref-type="bibr" rid="ref110">110</xref>). In animal models, 1-methyl-4-phenol-1,2,5,6-tetrahydropyridine (MPTP) is used to induce destruction of dopaminergic neurons in the substantia nigra, mimicking human Parkinson&#x2019;s-like syndrome (<xref ref-type="bibr" rid="ref111">111</xref>), while the infusion of BHB was found to have a protective role in dopaminergic neurodegeneration and motor deficits induced by MPTP (<xref ref-type="bibr" rid="ref112">112</xref>). Ketones also protect substantia nigra dopaminergic neurons against 6-hydroxydopamine neurotoxicity in a rat model of Parkinson&#x2019;s disease (<xref ref-type="bibr" rid="ref113">113</xref>). In Parkinson&#x2019;s disease patients, studies have revealed that high ketones are associated with improvements in Unified Parkinson&#x2019;s Disease Rating Scale (UPDRS) scores (<xref ref-type="bibr" rid="ref114">114</xref>).</p>
<p><italic>Brain cancer</italic> cells showed significant metabolic alterations with increased glucose and hydroperoxide metabolism compared to normal cells (<xref ref-type="bibr" rid="ref115">115</xref>). There is evidence that cancer cells are intolerant to ketones both <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="ref116">116</xref>). Preclinical studies have shown promising results for KD in reducing tumor growth and extending survival in the brain (<xref ref-type="bibr" rid="ref117">117</xref>), breast (<xref ref-type="bibr" rid="ref118">118</xref>), prostate (<xref ref-type="bibr" rid="ref119">119</xref>), and gastric cancer models (<xref ref-type="bibr" rid="ref120">120</xref>).</p>
<p>Exceptions: Despite KD showing a general benefit in many diseases, KD is not suitable for all diseases and even the formula of KD varies in different cases, raising the need for precision nutrition and nutrigenomic research.</p>
<p>For instance, not all cancer subtypes are amenable to KD. Some studies showed the absence of positive effects on tumor progression and survival with a 3:1 ratio of fatty acids to carbohydrates in a KD regimen in glioblastoma mouse models but changed to positive when the ratio increased to 4:1 or 6:1 (<xref ref-type="bibr" rid="ref117">117</xref>). On the contrary, in medulloblastoma mouse models, no change in survival or tumor progression was found even when the ratio of fatty acids to carbohydrates ratio was increased to 4:1 or 6:1 (<xref ref-type="bibr" rid="ref117">117</xref>). This also highlighted the need for precision nutrition in clinical practice.</p>
</sec>
<sec id="sec14">
<label>5.3</label>
<title>Concerns raised for ketogenic therapy call for personalized medicine</title>
<p>Notably, KD is used as a standard therapy for specific diseases and is not recommended for daily use by healthy people. Some case reports have even raised concerns about long-term KD use and under the background of some diseases. Despite its efficacy in the treatment of epilepsy from different causes, the benefits of KD rely on the integrity of the ketone body synthesis pathway. Inborn genetic errors in lipid metabolism such as membrane long-chain fatty acid transport, &#x03B2;-oxidation, and the Krebs cycle could be fatal when implementing fasting or KD (<xref ref-type="bibr" rid="ref121">121</xref>). Researchers highlighted that carnitine deficiency, carnitine palmitoyl-transferase I or II deficiency, carnitine translocase deficiency (<xref ref-type="bibr" rid="ref122">122</xref>), &#x03B2;-oxidation defects (<xref ref-type="bibr" rid="ref123">123</xref>), pyruvate carboxylase deficiency (<xref ref-type="bibr" rid="ref124">124</xref>) should be screened before KD treatments. Also, KD is not entirely free of side effects, with fatigue, muscle cramps, hypotension, constipation, and unwanted weight loss being the most commonly reported (<xref ref-type="bibr" rid="ref125">125</xref>). Although KD has been used by healthy people for weight loss, severe obesity is often driven or accompanied by a variety of metabolic disorders. The crosstalk for different metabolic pathological conditions should be emphasized, and fortunately the safety of long-term KD for weight loss is gradually being noticed (<xref ref-type="bibr" rid="ref49">49</xref>, <xref ref-type="bibr" rid="ref126">126</xref>). Thus, though KD is generally considered a safe treatment, there are limitations in current KD treatments and one should always weigh its long-term pros and cons before initiation (<xref ref-type="bibr" rid="ref127">127</xref>). A summary of concerns regarding KD treatment is provided below.</p>
<list list-type="bullet">
<list-item>
<p>Contraindications: liver failure, pancreatitis, inborn disorders of fat metabolism, primary carnitine deficiency, carnitine palmitoyltransferase deficiency, carnitine translocase deficiency, porphyria, and pyruvate kinase deficiency (<xref ref-type="bibr" rid="ref127">127</xref>).</p>
</list-item>
<list-item>
<p>Potential long-term side effects: hepatic steatosis, kidney stones, hypoproteinemia, and vitamin deficiency (<xref ref-type="bibr" rid="ref127">127</xref>).</p>
</list-item>
<list-item>
<p>Potential short-term side effects: keto breathiness and &#x201C;keto flu,&#x201D; which include fatigue, headache, dizziness, nausea, vomiting, constipation, low exercise tolerance, etc. (<xref ref-type="bibr" rid="ref127">127</xref>).</p>
</list-item>
<list-item>
<p>Incorrect medication dosing may cause severe hypoglycemia in diabetic patients (<xref ref-type="bibr" rid="ref127">127</xref>).</p>
</list-item>
<list-item>
<p>May lead to ketonemia and ketonuria (<xref ref-type="bibr" rid="ref127">127</xref>).</p>
</list-item>
<list-item>
<p>An increase in low-density lipoprotein cholesterol (LDL-C) levels may lead to atherosclerosis acceleration and increased CVD risk (<xref ref-type="bibr" rid="ref127">127</xref>).</p>
</list-item>
<list-item>
<p>More solid evaluation required in clinical trials: increased sample sizes, duration of interventions, decreased participant dropout rates, and follow-up for long-term response (<xref ref-type="bibr" rid="ref127">127</xref>).</p>
</list-item>
<list-item>
<p>Women with gestational diabetes mellitus are advised to avoid a ketone-elevating diet (<xref ref-type="bibr" rid="ref128">128</xref>).</p>
</list-item>
<list-item>
<p>KD is a lifelong treatment for some diseases, and therefore relatively low compliance rates (38% for CKD, 56% for MAD) were reported in a meta-analysis of 270 patients (<xref ref-type="bibr" rid="ref12">12</xref>).</p>
</list-item>
<list-item>
<p>The genomic variations between individuals may mean that the risks of KD may outweigh the benefits.</p>
</list-item>
</list>
</sec>
</sec>
<sec sec-type="conclusions" id="sec15">
<label>6</label>
<title>Conclusion</title>
<p>As an endogenous fuel that bridges metabolism to epigenetic regulation, the recent understanding of the function of ketones in both areas is encouraging for the development of new drugs for these previously identified &#x201C;incurable diseases.&#x201D; The benefits of ketogenic intervention in clinical practice are thusly highlighting its therapeutic potential for multiple brain diseases. Ketogenic intervention can be simply achieved through an associated diet that is relatively affordable and accessible. Growing evidence suggests that KD has a therapeutic effect on a wide range of human diseases, such potential makes KD an encouraging therapeutic strategy for many brain diseases. Being a low-side-effect treatment, elucidation of its therapeutic mechanism is a promising topic in the development of novel biotechnological drugs and synergistic therapy. However, the mechanism of KD benefits is still not fully understood, despite some evidence indicating its multiple targets and ability to regulate histone deacetylase, glycolysis, neurotransmitter levels, the function of NLRP3 inflammasome, and oxidative stress.</p>
<p>Moreover, KD is not suitable for all diseases and even the ratio difference in the KD formula may lead to unexpected therapeutic outcomes, thus increasing the need for precision nutrition and nutrigenomics research. A recent study revealed a distinct cell type&#x2013;specific KD response in the brain: metabolic plasticity is found in astrocytes and neurons, but not in oligodendrocytes (<xref ref-type="bibr" rid="ref129">129</xref>), which highlights the importance of narrowing the variation in KD responses. Available standards for clinical KD therapies are still very limited, and a certain level of precision nutrition is required as KD moves into clinical translation. Further studies to identify the clear mechanisms of KD and drug interactions, different KD responses in heterogeneous patient backgrounds, and clear mechanisms of KD intervention in the fight against numerous specific central nervous system diseases are crucial. In addition, in clinical applications, precision nutrition should also be considered as slight changes in dietary composition could impact/ameliorate the potential side effects of KD in certain populations.</p>
</sec>
<sec id="sec16">
<label>7</label>
<title>Open questions</title>
<list list-type="order">
<list-item>
<p>From an evolutionary point of view, how do we understand the physiological benefits of KD compared with a normal diet?</p>
</list-item>
<list-item>
<p>How do we define the drug interactions with KD in different individuals during the diagnosis and early treatment period?</p>
</list-item>
<list-item>
<p>Is it possible to trigger ketone production on a cell-specific or tissue-specific level?</p>
</list-item>
<list-item>
<p>Can KD regulate the immune system? Will combination therapies such as chemotherapy, immunotherapy, and KD improve the survival of cancer patients?</p>
</list-item>
<list-item>
<p>Can KD be a trigger for synergistic drug treatment?</p>
</list-item>
<list-item>
<p>What is the epigenetic map of patients following a KD regimen? Is there any drug or epigenetic regulator that can replace long-term KD administration?</p>
</list-item>
</list>
</sec>
<sec sec-type="author-contributions" id="sec17">
<title>Author contributions</title>
<p>YL: Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing, Conceptualization, Validation, Visualization. LF: Investigation, Visualization, Writing &#x2013; review &#x0026; editing. HY: Formal analysis, Validation, Visualization, Writing &#x2013; review &#x0026; editing. DW: Conceptualization, Validation, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. RL: Validation, Visualization, Writing &#x2013; review &#x0026; editing. TS: Conceptualization, Supervision, Validation, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. XX: Conceptualization, Formal analysis, Supervision, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="sec19">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (Grant No. 32001432), the Fellowship of China Postdoctoral Science Foundation (Grant No. 2021M690903), the Department of Science and Technology of Henan Province (202102110478), the Henan Province Medical Science and Technology Research Plan Joint project (LHGJ20210333), and the Department of Health of Zhejiang Province Technology Project, Health Committee of Zhejiang Province (2021KY382).</p>
</sec>
<ack>
<p>Illustrations created with <ext-link xlink:href="http://biorender.com" ext-link-type="uri">biorender.com</ext-link>.</p>
</ack>
<sec sec-type="COI-statement" id="sec20">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The reviewer ZC declared a shared affiliation with the author(s) TS to the handling editor at the time of review.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>H</given-names></name> <name><surname>Bi</surname> <given-names>D</given-names></name> <name><surname>Zhang</surname> <given-names>Y</given-names></name> <name><surname>Kong</surname> <given-names>C</given-names></name> <name><surname>Du</surname> <given-names>J</given-names></name> <name><surname>Wu</surname> <given-names>X</given-names></name> <etal/></person-group>. <article-title>Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2022</year>) <volume>7</volume>:<fpage>11</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-021-00831-w</pub-id>, PMID: <pub-id pub-id-type="pmid">35034957</pub-id></citation></ref>
<ref id="ref2"><label>2.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sampaio</surname> <given-names>LP</given-names></name></person-group>. <article-title>Ketogenic diet for epilepsy treatment</article-title>. <source>Arq Neuropsiquiatr</source>. (<year>2016</year>) <volume>74</volume>:<fpage>842</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1590/0004-282X20160116</pub-id></citation></ref>
<ref id="ref3"><label>3.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wheless</surname> <given-names>JW</given-names></name></person-group>. <article-title>History of the ketogenic diet</article-title>. <source>Epilepsia</source>. (<year>2008</year>) <volume>49</volume>:<fpage>3</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1528-1167.2008.01821.x</pub-id></citation></ref>
<ref id="ref4"><label>4.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname> <given-names>AA</given-names></name> <name><surname>Eroglu</surname> <given-names>EI</given-names></name> <name><surname>Rooney</surname> <given-names>K</given-names></name> <name><surname>Harper</surname> <given-names>C</given-names></name> <name><surname>McClintock</surname> <given-names>S</given-names></name> <name><surname>Franklin</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Urine dipsticks are not accurate for detecting mild ketosis during a severely energy restricted diet</article-title>. <source>Obes Sci Pract</source>. (<year>2020</year>) <volume>6</volume>:<fpage>544</fpage>&#x2013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1002/osp4.432</pub-id></citation></ref>
<ref id="ref5"><label>5.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kossoff</surname> <given-names>EH</given-names></name> <name><surname>Zupec-Kania</surname> <given-names>BA</given-names></name> <name><surname>Auvin</surname> <given-names>S</given-names></name> <name><surname>Ballaban-Gil</surname> <given-names>KR</given-names></name> <name><surname>Christina Bergqvist</surname> <given-names>AG</given-names></name> <name><surname>Blackford</surname> <given-names>R</given-names></name> <etal/></person-group>. <article-title>Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the international ketogenic diet study group</article-title>. <source>Epilepsia Open</source>. (<year>2018</year>) <volume>3</volume>:<fpage>175</fpage>&#x2013;<lpage>92</lpage>. doi: <pub-id pub-id-type="doi">10.1002/epi4.12225</pub-id>, PMID: <pub-id pub-id-type="pmid">29881797</pub-id></citation></ref>
<ref id="ref6"><label>6.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>W</given-names></name> <name><surname>Kossoff</surname> <given-names>EH</given-names></name></person-group>. <article-title>Long-term follow-up of children treated with the modified Atkins diet</article-title>. <source>J Child Neurol</source>. (<year>2012</year>) <volume>27</volume>:<fpage>754</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0883073812441062</pub-id></citation></ref>
<ref id="ref7"><label>7.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>D&#x2019;Andrea Meira</surname> <given-names>I</given-names></name> <name><surname>Rom&#x00E3;o</surname> <given-names>TT</given-names></name> <name><surname>Pires do Prado</surname> <given-names>HJ</given-names></name> <name><surname>Kr&#x00FC;ger</surname> <given-names>LT</given-names></name> <name><surname>MEP</surname> <given-names>P</given-names></name> <name><surname>da Concei&#x00E7;&#x00E3;o</surname> <given-names>PO</given-names></name></person-group>. <article-title>Ketogenic diet and epilepsy: what we know so far</article-title>. <source>Front Neurosci</source>. (<year>2019</year>) <volume>13</volume>:<fpage>5</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2019.00005</pub-id></citation></ref>
<ref id="ref8"><label>8.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhamija</surname> <given-names>R</given-names></name> <name><surname>Eckert</surname> <given-names>S</given-names></name> <name><surname>Wirrell</surname> <given-names>E</given-names></name></person-group>. <article-title>Ketogenic diet</article-title>. <source>Can J Neurol Sci</source>. (<year>2013</year>) <volume>40</volume>:<fpage>158</fpage>&#x2013;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S0317167100013676</pub-id></citation></ref>
<ref id="ref9"><label>9.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grocott</surname> <given-names>OR</given-names></name> <name><surname>Herrington</surname> <given-names>KS</given-names></name> <name><surname>Pfeifer</surname> <given-names>HH</given-names></name> <name><surname>Thiele</surname> <given-names>EA</given-names></name> <name><surname>Thibert</surname> <given-names>RL</given-names></name></person-group>. <article-title>Low glycemic index treatment for seizure control in Angelman syndrome: a case series from the Center for Dietary Therapy of epilepsy at the Massachusetts General Hospital</article-title>. <source>Epilepsy Behav</source>. (<year>2017</year>) <volume>68</volume>:<fpage>45</fpage>&#x2013;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.yebeh.2016.12.018</pub-id>, PMID: <pub-id pub-id-type="pmid">28109989</pub-id></citation></ref>
<ref id="ref10"><label>10.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname> <given-names>TJW</given-names></name> <name><surname>Cervenka</surname> <given-names>MC</given-names></name></person-group>. <article-title>Ketogenic diets for adults with highly refractory epilepsy</article-title>. <source>Epilepsy Currents</source>. (<year>2017</year>) <volume>17</volume>:<fpage>346</fpage>&#x2013;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.5698/1535-7597.17.6.346</pub-id></citation></ref>
<ref id="ref11"><label>11.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>YM</given-names></name> <name><surname>Wang</surname> <given-names>HS</given-names></name></person-group>. <article-title>Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets</article-title>. <source>Biom J</source>. (<year>2013</year>) <volume>36</volume>:<fpage>9</fpage>&#x2013;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.4103/2319-4170.107154</pub-id>, PMID: <pub-id pub-id-type="pmid">23515148</pub-id></citation></ref>
<ref id="ref12"><label>12.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>F</given-names></name> <name><surname>Li</surname> <given-names>XJ</given-names></name> <name><surname>Jiang</surname> <given-names>WL</given-names></name> <name><surname>Sun</surname> <given-names>HB</given-names></name> <name><surname>Liu</surname> <given-names>J</given-names></name></person-group>. <article-title>Efficacy of and patient compliance with a ketogenic diet in adults with intractable epilepsy: a meta-analysis</article-title>. <source>J Clin Neurol</source>. (<year>2015</year>) <volume>11</volume>:<fpage>26</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.3988/jcn.2015.11.1.26</pub-id>, PMID: <pub-id pub-id-type="pmid">25628734</pub-id></citation></ref>
<ref id="ref13"><label>13.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leroy</surname> <given-names>F</given-names></name> <name><surname>Smith</surname> <given-names>NW</given-names></name> <name><surname>Adesogan</surname> <given-names>AT</given-names></name> <name><surname>Beal</surname> <given-names>T</given-names></name> <name><surname>Iannotti</surname> <given-names>L</given-names></name> <name><surname>Moughan</surname> <given-names>PJ</given-names></name> <etal/></person-group>. <article-title>The role of meat in the human diet: evolutionary aspects and nutritional value</article-title>. <source>Anim Front</source>. (<year>2023</year>) <volume>13</volume>:<fpage>11</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1093/af/vfac093</pub-id>, PMID: <pub-id pub-id-type="pmid">37073319</pub-id></citation></ref>
<ref id="ref14"><label>14.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cunnane</surname> <given-names>SC</given-names></name> <name><surname>Crawford</surname> <given-names>MA</given-names></name></person-group>. <article-title>Survival of the fattest: fat babies were the key to evolution of the large human brain</article-title>. <source>Comp Biochem Physiol A Mol Integr Physiol</source>. (<year>2003</year>) <volume>136</volume>:<fpage>17</fpage>&#x2013;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1095-6433(03)00048-5</pub-id>, PMID: <pub-id pub-id-type="pmid">14527626</pub-id></citation></ref>
<ref id="ref15"><label>15.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>SP</given-names></name> <name><surname>Yang</surname> <given-names>H</given-names></name> <name><surname>Wu</surname> <given-names>JW</given-names></name> <name><surname>Gauthier</surname> <given-names>N</given-names></name> <name><surname>Fukao</surname> <given-names>T</given-names></name> <name><surname>Mitchell</surname> <given-names>GA</given-names></name></person-group>. <article-title>Metabolism as a tool for understanding human brain evolution: lipid energy metabolism as an example</article-title>. <source>J Hum Evol</source>. (<year>2014</year>) <volume>77</volume>:<fpage>41</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jhevol.2014.06.013</pub-id>, PMID: <pub-id pub-id-type="pmid">25488255</pub-id></citation></ref>
<ref id="ref16"><label>16.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasselbalch</surname> <given-names>SG</given-names></name> <name><surname>Knudsen</surname> <given-names>GM</given-names></name> <name><surname>Jakobsen</surname> <given-names>J</given-names></name> <name><surname>Hageman</surname> <given-names>LP</given-names></name> <name><surname>Holm</surname> <given-names>S</given-names></name> <name><surname>Paulson</surname> <given-names>OB</given-names></name></person-group>. <article-title>Blood-brain barrier permeability of glucose and ketone bodies during short-term starvation in humans</article-title>. <source>Am J Physiol</source>. (<year>1995</year>) <volume>268</volume>:<fpage>E1161</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajpendo.1995.268.6.E1161</pub-id>, PMID: <pub-id pub-id-type="pmid">7611392</pub-id></citation></ref>
<ref id="ref17"><label>17.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Speakman</surname> <given-names>JR</given-names></name> <name><surname>O'Rahilly</surname> <given-names>S</given-names></name></person-group>. <article-title>Fat: an evolving issue</article-title>. <source>Dis Model Mech</source>. (<year>2012</year>) <volume>5</volume>:<fpage>569</fpage>&#x2013;<lpage>73</lpage>. doi: <pub-id pub-id-type="doi">10.1242/dmm.010553</pub-id>, PMID: <pub-id pub-id-type="pmid">22915015</pub-id></citation></ref>
<ref id="ref18"><label>18.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oyarz&#x00E1;bal</surname> <given-names>A</given-names></name> <name><surname>Musokhranova</surname> <given-names>U</given-names></name> <name><surname>Barros</surname> <given-names>L</given-names></name> <name><surname>Garc&#x00ED;a-Cazorla</surname> <given-names>A</given-names></name></person-group>. <article-title>Energy metabolism in childhood neurodevelopmental disorders</article-title>. <source>EBioMedicine</source>. (<year>2021</year>) <volume>69</volume>:<fpage>103474</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103474</pub-id>, PMID: <pub-id pub-id-type="pmid">34256347</pub-id></citation></ref>
<ref id="ref19"><label>19.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berghoff</surname> <given-names>SA</given-names></name> <name><surname>Spieth</surname> <given-names>L</given-names></name> <name><surname>Saher</surname> <given-names>G</given-names></name></person-group>. <article-title>Local cholesterol metabolism orchestrates remyelination</article-title>. <source>Trends Neurosci</source>. (<year>2022</year>) <volume>45</volume>:<fpage>272</fpage>&#x2013;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tins.2022.01.001</pub-id>, PMID: <pub-id pub-id-type="pmid">35153084</pub-id></citation></ref>
<ref id="ref20"><label>20.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mu</surname> <given-names>J</given-names></name> <name><surname>Wang</surname> <given-names>T</given-names></name> <name><surname>Li</surname> <given-names>M</given-names></name> <name><surname>Guan</surname> <given-names>T</given-names></name> <name><surname>Guo</surname> <given-names>Y</given-names></name> <name><surname>Zhang</surname> <given-names>X</given-names></name> <etal/></person-group>. <article-title>Ketogenic diet protects myelin and axons in diffuse axonal injury</article-title>. <source>Nutr Neurosci</source>. (<year>2022</year>) <volume>25</volume>:<fpage>1534</fpage>&#x2013;<lpage>47</lpage>. doi: <pub-id pub-id-type="doi">10.1080/1028415X.2021.1875300</pub-id>, PMID: <pub-id pub-id-type="pmid">33487123</pub-id></citation></ref>
<ref id="ref21"><label>21.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cotter</surname> <given-names>DG</given-names></name> <name><surname>d'Avignon</surname> <given-names>DA</given-names></name> <name><surname>Wentz</surname> <given-names>AE</given-names></name> <name><surname>Weber</surname> <given-names>ML</given-names></name> <name><surname>Crawford</surname> <given-names>PA</given-names></name></person-group>. <article-title>Obligate role for ketone body oxidation in neonatal metabolic homeostasis&#x002A;</article-title>. <source>J Biol Chem</source>. (<year>2011</year>) <volume>286</volume>:<fpage>6902</fpage>&#x2013;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M110.192369</pub-id>, PMID: <pub-id pub-id-type="pmid">21209089</pub-id></citation></ref>
<ref id="ref22"><label>22.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rafiki</surname> <given-names>A</given-names></name> <name><surname>Boulland</surname> <given-names>JL</given-names></name> <name><surname>Halestrap</surname> <given-names>AP</given-names></name> <name><surname>Ottersen</surname> <given-names>OP</given-names></name> <name><surname>Bergersen</surname> <given-names>L</given-names></name></person-group>. <article-title>Highly differential expression of the monocarboxylate transporters MCT2 and MCT4 in the developing rat brain</article-title>. <source>Neuroscience</source>. (<year>2003</year>) <volume>122</volume>:<fpage>677</fpage>&#x2013;<lpage>88</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroscience.2003.08.040</pub-id>, PMID: <pub-id pub-id-type="pmid">14622911</pub-id></citation></ref>
<ref id="ref23"><label>23.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noshiro</surname> <given-names>K</given-names></name> <name><surname>Umazume</surname> <given-names>T</given-names></name> <name><surname>Hattori</surname> <given-names>R</given-names></name> <name><surname>Kataoka</surname> <given-names>S</given-names></name> <name><surname>Yamada</surname> <given-names>T</given-names></name> <name><surname>Watari</surname> <given-names>H</given-names></name></person-group>. <article-title>Changes in serum levels of ketone bodies and human chorionic gonadotropin during pregnancy in relation to the neonatal body shape: a retrospective analysis</article-title>. <source>Nutrients</source>. (<year>2022</year>) <volume>14</volume>:<fpage>1971</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu14091971</pub-id></citation></ref>
<ref id="ref24"><label>24.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dardzinski</surname> <given-names>BJ</given-names></name> <name><surname>Smith</surname> <given-names>SL</given-names></name> <name><surname>Towfighi</surname> <given-names>J</given-names></name> <name><surname>Williams</surname> <given-names>GD</given-names></name> <name><surname>Vannucci</surname> <given-names>RC</given-names></name> <name><surname>Smith</surname> <given-names>MB</given-names></name></person-group>. <article-title>Increased plasma Beta-Hydroxybutyrate, preserved cerebral energy metabolism, and amelioration of brain damage during neonatal hypoxia ischemia with dexamethasone pretreatment</article-title>. <source>Pediatr Res</source>. (<year>2000</year>) <volume>48</volume>:<fpage>248</fpage>&#x2013;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1203/00006450-200008000-00021</pub-id>, PMID: <pub-id pub-id-type="pmid">10926303</pub-id></citation></ref>
<ref id="ref25"><label>25.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Y</given-names></name> <name><surname>Sun</surname> <given-names>L</given-names></name> <name><surname>Wang</surname> <given-names>H</given-names></name></person-group>. <article-title>Ketogenic diet for neonatal hypoxic&#x2013;ischemic encephalopathy</article-title>. <source>ACS Chem Neurosci</source>. (<year>2023</year>) <volume>14</volume>:<fpage>1</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acschemneuro.2c00609</pub-id>, PMID: <pub-id pub-id-type="pmid">36541291</pub-id></citation></ref>
<ref id="ref26"><label>26.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>P&#x00E9;rez-Li&#x00E9;bana</surname> <given-names>I</given-names></name> <name><surname>Casarejos</surname> <given-names>MJ</given-names></name> <name><surname>Alcaide</surname> <given-names>A</given-names></name> <name><surname>Herrada-Soler</surname> <given-names>E</given-names></name> <name><surname>Llorente-Folch</surname> <given-names>I</given-names></name> <name><surname>Contreras</surname> <given-names>L</given-names></name> <etal/></person-group>. <article-title>&#x03B2;OHB protective pathways in Aralar-KO neurons and brain: an alternative to ketogenic diet</article-title>. <source>J Neurosci</source>. (<year>2020</year>) <volume>40</volume>:<fpage>9293</fpage>&#x2013;<lpage>305</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0711-20.2020</pub-id>, PMID: <pub-id pub-id-type="pmid">33087477</pub-id></citation></ref>
<ref id="ref27"><label>27.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>BS</given-names></name> <name><surname>Woo</surname> <given-names>DC</given-names></name> <name><surname>Woo</surname> <given-names>CW</given-names></name> <name><surname>Kim</surname> <given-names>KS</given-names></name></person-group>. <article-title>Exogenous &#x03B2;-Hydroxybutyrate treatment and neuroprotection in a suckling rat model of hypoxic-ischemic encephalopathy</article-title>. <source>Dev Neurosci</source>. (<year>2018</year>) <volume>40</volume>:<fpage>73</fpage>&#x2013;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000486411</pub-id>, PMID: <pub-id pub-id-type="pmid">29466799</pub-id></citation></ref>
<ref id="ref28"><label>28.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stumpf</surname> <given-names>SK</given-names></name> <name><surname>Berghoff</surname> <given-names>SA</given-names></name> <name><surname>Trevisiol</surname> <given-names>A</given-names></name> <name><surname>Spieth</surname> <given-names>L</given-names></name> <name><surname>D&#x00FC;king</surname> <given-names>T</given-names></name> <name><surname>Schneider</surname> <given-names>LV</given-names></name> <etal/></person-group>. <article-title>Ketogenic diet ameliorates axonal defects and promotes myelination in Pelizaeus&#x2013;Merzbacher disease</article-title>. <source>Acta Neuropathol</source>. (<year>2019</year>) <volume>138</volume>:<fpage>147</fpage>&#x2013;<lpage>61</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00401-019-01985-2</pub-id>, PMID: <pub-id pub-id-type="pmid">30919030</pub-id></citation></ref>
<ref id="ref29"><label>29.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tiulganova</surname> <given-names>DA</given-names></name> <name><surname>Nasaev</surname> <given-names>SS</given-names></name> <name><surname>Chugreev</surname> <given-names>IA</given-names></name> <name><surname>Rodionova</surname> <given-names>MA</given-names></name> <name><surname>Zavyalov</surname> <given-names>GA</given-names></name></person-group>. <article-title>Mechanisms of ketogenic diet action</article-title>. <source>Zh Nevrol Psikhiatr Im S S Korsakova</source>. (<year>2018</year>) <volume>118</volume>:<fpage>72</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.17116/jnevro201811810272</pub-id></citation></ref>
<ref id="ref30"><label>30.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dilliraj</surname> <given-names>LN</given-names></name> <name><surname>Schiuma</surname> <given-names>G</given-names></name> <name><surname>Lara</surname> <given-names>D</given-names></name> <name><surname>Strazzabosco</surname> <given-names>G</given-names></name> <name><surname>Clement</surname> <given-names>J</given-names></name> <name><surname>Giovannini</surname> <given-names>P</given-names></name> <etal/></person-group>. <article-title>The evolution of ketosis: potential impact on clinical conditions</article-title>. <source>Nutrients</source>. (<year>2022</year>) <volume>14</volume>:<fpage>3613</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu14173613</pub-id></citation></ref>
<ref id="ref31"><label>31.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sacchetti</surname> <given-names>P</given-names></name> <name><surname>Jain</surname> <given-names>S</given-names></name> <name><surname>Yadav</surname> <given-names>H</given-names></name> <name><surname>Paoli</surname> <given-names>A</given-names></name></person-group>. <article-title>Editorial: impact of ketogenic diet on metabolic and brain health</article-title>. <source>Front Neurosci</source>. (<year>2023</year>) <volume>16</volume>:<fpage>1107741</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2022.1107741</pub-id>, PMID: <pub-id pub-id-type="pmid">36699514</pub-id></citation></ref>
<ref id="ref32"><label>32.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gough</surname> <given-names>SM</given-names></name> <name><surname>Casella</surname> <given-names>A</given-names></name> <name><surname>Ortega</surname> <given-names>KJ</given-names></name></person-group>. <article-title>Neuroprotection by the ketogenic diet: evidence and controversies</article-title>. <source>Front Nutr</source>. (<year>2021</year>) <volume>8</volume>:<fpage>782657</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnut.2021.782657</pub-id>, PMID: <pub-id pub-id-type="pmid">34888340</pub-id></citation></ref>
<ref id="ref33"><label>33.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mujica-Parodi</surname> <given-names>LR</given-names></name> <name><surname>Amgalan</surname> <given-names>A</given-names></name> <name><surname>Sultan</surname> <given-names>SF</given-names></name> <name><surname>Antal</surname> <given-names>B</given-names></name> <name><surname>Sun</surname> <given-names>X</given-names></name> <name><surname>Skiena</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>Diet modulates brain network stability, a biomarker for brain aging, in young adults</article-title>. <source>Proc Natl Acad Sci</source>. (<year>2020</year>) <volume>117</volume>:<fpage>6170</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1913042117</pub-id>, PMID: <pub-id pub-id-type="pmid">32127481</pub-id></citation></ref>
<ref id="ref34"><label>34.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>J</given-names></name> <name><surname>Liu</surname> <given-names>Y</given-names></name> <name><surname>Liu</surname> <given-names>H-Q</given-names></name> <name><surname>Chen</surname> <given-names>L</given-names></name> <name><surname>Li</surname> <given-names>R-J</given-names></name></person-group>. <article-title>Ketogenic diet potentiates electrical stimulation&#x2013;induced peripheral nerve regeneration after sciatic nerve crush injury in rats</article-title>. <source>Mol Nutr Food Res</source>. (<year>2020</year>) <volume>64</volume>:<fpage>1900535</fpage>. doi: <pub-id pub-id-type="doi">10.1002/mnfr.201900535</pub-id></citation></ref>
<ref id="ref35"><label>35.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>Z</given-names></name> <name><surname>Lange</surname> <given-names>DJ</given-names></name> <name><surname>Voustianiouk</surname> <given-names>A</given-names></name> <name><surname>Mac Grogan</surname> <given-names>D</given-names></name> <name><surname>Ho</surname> <given-names>L</given-names></name> <name><surname>Suh</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis</article-title>. <source>BMC Neurosci</source>. (<year>2006</year>) <volume>7</volume>:<fpage>29</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2202-7-29</pub-id>, PMID: <pub-id pub-id-type="pmid">16584562</pub-id></citation></ref>
<ref id="ref36"><label>36.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caplliure-Llopis</surname> <given-names>J</given-names></name> <name><surname>Peralta-Chamba</surname> <given-names>T</given-names></name> <name><surname>Carrera-Juli&#x00E1;</surname> <given-names>S</given-names></name> <name><surname>Cuerda-Ballester</surname> <given-names>M</given-names></name> <name><surname>Drehmer-Rieger</surname> <given-names>E</given-names></name> <name><surname>L&#x00F3;pez-Rodriguez</surname> <given-names>MM</given-names></name> <etal/></person-group>. <article-title>Therapeutic alternative of the ketogenic Mediterranean diet to improve mitochondrial activity in amyotrophic lateral sclerosis (ALS): a comprehensive</article-title>. <source>Review</source>. (<year>2020</year>) <volume>8</volume>:<fpage>23</fpage>&#x2013;<lpage>35</lpage>. doi: <pub-id pub-id-type="doi">10.1002/fsn3.1324</pub-id>, PMID: <pub-id pub-id-type="pmid">31993129</pub-id></citation></ref>
<ref id="ref37"><label>37.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veyrat-Durebex</surname> <given-names>C</given-names></name> <name><surname>Reynier</surname> <given-names>P</given-names></name> <name><surname>Procaccio</surname> <given-names>V</given-names></name> <name><surname>Hergesheimer</surname> <given-names>R</given-names></name> <name><surname>Corcia</surname> <given-names>P</given-names></name> <name><surname>Andres</surname> <given-names>CR</given-names></name> <etal/></person-group>. <article-title>How can a ketogenic diet improve motor function?</article-title> <source>Front Mol Neurosci</source>. (<year>2018</year>) <volume>11</volume>:<fpage>15</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2018.00015</pub-id></citation></ref>
<ref id="ref38"><label>38.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname> <given-names>NJ</given-names></name> <name><surname>Wodschow</surname> <given-names>HZ</given-names></name> <name><surname>Nilsson</surname> <given-names>M</given-names></name> <name><surname>Rungby</surname> <given-names>J</given-names></name></person-group>. <article-title>Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases</article-title>. <source>Int J Mol Sci</source>. (<year>2020</year>) <volume>21</volume>:<fpage>8767</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21228767</pub-id>, PMID: <pub-id pub-id-type="pmid">33233502</pub-id></citation></ref>
<ref id="ref39"><label>39.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname> <given-names>JC</given-names></name> <name><surname>Verdin</surname> <given-names>E</given-names></name></person-group>. <article-title>beta-Hydroxybutyrate: a signaling metabolite</article-title>. <source>Annu Rev Nutr</source>. (<year>2017</year>) <volume>37</volume>:<fpage>51</fpage>&#x2013;<lpage>76</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-nutr-071816-064916</pub-id>, PMID: <pub-id pub-id-type="pmid">28826372</pub-id></citation></ref>
<ref id="ref40"><label>40.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Offermanns</surname> <given-names>S</given-names></name> <name><surname>Schwaninger</surname> <given-names>M</given-names></name></person-group>. <article-title>Nutritional or pharmacological activation of HCA2 ameliorates neuroinflammation</article-title>. <source>Trends Mol Med</source>. (<year>2015</year>) <volume>21</volume>:<fpage>245</fpage>&#x2013;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molmed.2015.02.002</pub-id>, PMID: <pub-id pub-id-type="pmid">25766751</pub-id></citation></ref>
<ref id="ref41"><label>41.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lutas</surname> <given-names>A</given-names></name> <name><surname>Yellen</surname> <given-names>G</given-names></name></person-group>. <article-title>The ketogenic diet: metabolic influences on brain excitability and epilepsy</article-title>. <source>Trends Neurosci</source>. (<year>2013</year>) <volume>36</volume>:<fpage>32</fpage>&#x2013;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tins.2012.11.005</pub-id>, PMID: <pub-id pub-id-type="pmid">23228828</pub-id></citation></ref>
<ref id="ref42"><label>42.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rho</surname> <given-names>JM</given-names></name></person-group>. <article-title>How does the ketogenic diet induce anti-seizure effects?</article-title> <source>Neurosci Lett</source>. (<year>2017</year>) <volume>637</volume>:<fpage>4</fpage>&#x2013;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neulet.2015.07.034</pub-id></citation></ref>
<ref id="ref43"><label>43.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimazu</surname> <given-names>T</given-names></name> <name><surname>Hirschey</surname> <given-names>MD</given-names></name> <name><surname>Newman</surname> <given-names>J</given-names></name> <name><surname>He</surname> <given-names>W</given-names></name> <name><surname>Shirakawa</surname> <given-names>K</given-names></name> <name><surname>Le Moan</surname> <given-names>N</given-names></name> <etal/></person-group>. <article-title>Suppression of oxidative stress by &#x03B2;-hydroxybutyrate, an endogenous histone deacetylase inhibitor</article-title>. <source>Science (New York, NY)</source>. (<year>2013</year>) <volume>339</volume>:<fpage>211</fpage>&#x2013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1227166</pub-id>, PMID: <pub-id pub-id-type="pmid">23223453</pub-id></citation></ref>
<ref id="ref44"><label>44.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X</given-names></name> <name><surname>Wu</surname> <given-names>X</given-names></name> <name><surname>Liu</surname> <given-names>Q</given-names></name> <name><surname>Kong</surname> <given-names>G</given-names></name> <name><surname>Zhou</surname> <given-names>J</given-names></name> <name><surname>Jiang</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Ketogenic metabolism inhibits histone deacetylase (HDAC) and reduces oxidative stress after spinal cord injury in rats</article-title>. <source>Neuroscience</source>. (<year>2017</year>) <volume>366</volume>:<fpage>36</fpage>&#x2013;<lpage>43</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroscience.2017.09.056</pub-id>, PMID: <pub-id pub-id-type="pmid">29024787</pub-id></citation></ref>
<ref id="ref45"><label>45.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname> <given-names>CL</given-names></name> <name><surname>Mobbs</surname> <given-names>CV</given-names></name></person-group>. <article-title>Epigenetic mechanisms underlying lifespan and age-related effects of dietary restriction and the ketogenic diet</article-title>. <source>Mol Cell Endocrinol</source>. (<year>2017</year>) <volume>455</volume>:<fpage>33</fpage>&#x2013;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mce.2016.11.013</pub-id>, PMID: <pub-id pub-id-type="pmid">27884781</pub-id></citation></ref>
<ref id="ref46"><label>46.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname> <given-names>DD</given-names></name> <name><surname>Aminzadeh-Gohari</surname> <given-names>S</given-names></name> <name><surname>Tulipan</surname> <given-names>J</given-names></name> <name><surname>Catalano</surname> <given-names>L</given-names></name> <name><surname>Feichtinger</surname> <given-names>RG</given-names></name> <name><surname>Kofler</surname> <given-names>B</given-names></name></person-group>. <article-title>Ketogenic diet in the treatment of cancer - where do we stand?</article-title> <source>Mol Metab</source>. (<year>2020</year>) <volume>33</volume>:<fpage>102</fpage>&#x2013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molmet.2019.06.026</pub-id>, PMID: <pub-id pub-id-type="pmid">31399389</pub-id></citation></ref>
<ref id="ref47"><label>47.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname> <given-names>Y</given-names></name> <name><surname>Wang</surname> <given-names>H</given-names></name> <name><surname>Liu</surname> <given-names>X</given-names></name> <name><surname>Zhang</surname> <given-names>J</given-names></name> <name><surname>Liu</surname> <given-names>G</given-names></name></person-group>. <article-title>Crosstalk between the ketogenic diet and epilepsy: from the perspective of gut microbiota</article-title>. <source>Mediat Inflamm</source>. (<year>2019</year>) <volume>2019</volume>:<fpage>1</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1155/2019/8373060</pub-id></citation></ref>
<ref id="ref48"><label>48.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname> <given-names>CA</given-names></name> <name><surname>Vuong</surname> <given-names>HE</given-names></name> <name><surname>Yano</surname> <given-names>JM</given-names></name> <name><surname>Liang</surname> <given-names>QY</given-names></name> <name><surname>Nusbaum</surname> <given-names>DJ</given-names></name> <name><surname>Hsiao</surname> <given-names>EY</given-names></name></person-group>. <article-title>The gut microbiota mediates the anti-seizure effects of the ketogenic diet</article-title>. <source>Cell</source>. (<year>2018</year>) <volume>173</volume>:<fpage>1728</fpage>&#x2013;<lpage>1741.e13</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2018.04.027</pub-id>, PMID: <pub-id pub-id-type="pmid">29804833</pub-id></citation></ref>
<ref id="ref49"><label>49.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname> <given-names>Y</given-names></name> <name><surname>Song</surname> <given-names>H</given-names></name> <name><surname>Holmes</surname> <given-names>A</given-names></name> <name><surname>Yan</surname> <given-names>J</given-names></name> <name><surname>Ren</surname> <given-names>C</given-names></name> <name><surname>Zhang</surname> <given-names>Y</given-names></name> <etal/></person-group>. <article-title>Normal diet ameliorates obesity more safely and effectively than ketogenic diet does in high-fat diet-induced obesity mouse based on gut microbiota and lipid metabolism</article-title>. <source>Int J Food Sci Nutr</source>. (<year>2023</year>) <volume>74</volume>:<fpage>589</fpage>&#x2013;<lpage>605</lpage>. doi: <pub-id pub-id-type="doi">10.1080/09637486.2023.2235899</pub-id>, PMID: <pub-id pub-id-type="pmid">37475128</pub-id></citation></ref>
<ref id="ref50"><label>50.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jarrett</surname> <given-names>SG</given-names></name> <name><surname>Milder</surname> <given-names>JB</given-names></name> <name><surname>Liang</surname> <given-names>LP</given-names></name> <name><surname>Patel</surname> <given-names>M</given-names></name></person-group>. <article-title>The ketogenic diet increases mitochondrial glutathione levels</article-title>. <source>J Neurochem</source>. (<year>2008</year>) <volume>106</volume>:<fpage>1044</fpage>&#x2013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05460.x</pub-id>, PMID: <pub-id pub-id-type="pmid">18466343</pub-id></citation></ref>
<ref id="ref51"><label>51.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milder</surname> <given-names>JB</given-names></name> <name><surname>Liang</surname> <given-names>LP</given-names></name> <name><surname>Patel</surname> <given-names>M</given-names></name></person-group>. <article-title>Acute oxidative stress and systemic Nrf 2 activation by the ketogenic diet</article-title>. <source>Neurobiol Dis</source>. (<year>2010</year>) <volume>40</volume>:<fpage>238</fpage>&#x2013;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2010.05.030</pub-id>, PMID: <pub-id pub-id-type="pmid">20594978</pub-id></citation></ref>
<ref id="ref52"><label>52.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname> <given-names>S</given-names></name> <name><surname>Badana</surname> <given-names>AK</given-names></name> <name><surname>G</surname> <given-names>MM</given-names></name> <name><surname>G</surname> <given-names>S</given-names></name> <name><surname>Malla</surname> <given-names>RR</given-names></name></person-group>. <article-title>Reactive oxygen species: a key constituent in Cancer survival</article-title>. <source>Biomark Insights</source>. (<year>2018</year>) <volume>13</volume>:<fpage>117727191875539</fpage>. doi: <pub-id pub-id-type="doi">10.1177/1177271918755391</pub-id>, PMID: <pub-id pub-id-type="pmid">29449774</pub-id></citation></ref>
<ref id="ref53"><label>53.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scheck</surname> <given-names>AC</given-names></name> <name><surname>Abdelwahab</surname> <given-names>MG</given-names></name> <name><surname>Fenton</surname> <given-names>KE</given-names></name> <name><surname>Stafford</surname> <given-names>P</given-names></name></person-group>. <article-title>The ketogenic diet for the treatment of glioma: insights from genetic profiling</article-title>. <source>Epilepsy Res</source>. (<year>2012</year>) <volume>100</volume>:<fpage>327</fpage>&#x2013;<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eplepsyres.2011.09.022</pub-id>, PMID: <pub-id pub-id-type="pmid">22019313</pub-id></citation></ref>
<ref id="ref54"><label>54.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Byrne</surname> <given-names>NJ</given-names></name> <name><surname>Soni</surname> <given-names>S</given-names></name> <name><surname>Takahara</surname> <given-names>S</given-names></name> <name><surname>Ferdaoussi</surname> <given-names>M</given-names></name> <name><surname>Batran</surname> <given-names>RA</given-names></name> <name><surname>Darwesh</surname> <given-names>AM</given-names></name> <etal/></person-group>. <article-title>Chronically elevating circulating ketones can reduce cardiac inflammation and blunt the development of heart failure</article-title>. <source>Circ Heart Fail</source>. (<year>2020</year>) <volume>13</volume>:<fpage>e006573</fpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.119.006573</pub-id>, PMID: <pub-id pub-id-type="pmid">32493060</pub-id></citation></ref>
<ref id="ref55"><label>55.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname> <given-names>H</given-names></name> <name><surname>Lu</surname> <given-names>Y</given-names></name> <name><surname>Huang</surname> <given-names>M-J</given-names></name> <name><surname>Yang</surname> <given-names>Y-Y</given-names></name> <name><surname>Xing</surname> <given-names>H-Y</given-names></name> <name><surname>Liu</surname> <given-names>X-X</given-names></name> <etal/></person-group>. <article-title>Ketogenic diet-mediated steroid metabolism reprogramming improves the immune microenvironment and myelin growth in spinal cord injury rats according to gene and co-expression network analyses</article-title>. <source>Aging (Albany NY)</source>. (<year>2021</year>) <volume>13</volume>:<fpage>12973</fpage>&#x2013;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.18632/aging.202969</pub-id>, PMID: <pub-id pub-id-type="pmid">33962394</pub-id></citation></ref>
<ref id="ref56"><label>56.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname> <given-names>M</given-names></name> <name><surname>Thaiss</surname> <given-names>CA</given-names></name> <name><surname>Elinav</surname> <given-names>E</given-names></name></person-group>. <article-title>Taming the inflammasome</article-title>. <source>Nat Med</source>. (<year>2015</year>) <volume>21</volume>:<fpage>213</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nm.3808</pub-id>, PMID: <pub-id pub-id-type="pmid">25742454</pub-id></citation></ref>
<ref id="ref57"><label>57.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ashley</surname> <given-names>EA</given-names></name></person-group>. <article-title>Towards precision medicine</article-title>. <source>Nat Rev Genet</source>. (<year>2016</year>) <volume>17</volume>:<fpage>507</fpage>&#x2013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrg.2016.86</pub-id></citation></ref>
<ref id="ref58"><label>58.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kosorok</surname> <given-names>MR</given-names></name> <name><surname>Laber</surname> <given-names>EB</given-names></name></person-group>. <article-title>Precision Medicine</article-title>. <source>Annu Rev Stat Appl</source>. (<year>2019</year>) <volume>6</volume>:<fpage>263</fpage>&#x2013;<lpage>86</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-statistics-030718-105251</pub-id>, PMID: <pub-id pub-id-type="pmid">31073534</pub-id></citation></ref>
<ref id="ref59"><label>59.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muir</surname> <given-names>A</given-names></name> <name><surname>Vander Heiden</surname> <given-names>MG</given-names></name></person-group>. <article-title>The nutrient environment affects therapy</article-title>. <source>Science</source>. (<year>2018</year>) <volume>360</volume>:<fpage>962</fpage>&#x2013;<lpage>3</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.aar5986</pub-id>, PMID: <pub-id pub-id-type="pmid">29853672</pub-id></citation></ref>
<ref id="ref60"><label>60.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denny</surname> <given-names>JC</given-names></name> <name><surname>Collins</surname> <given-names>FS</given-names></name></person-group>. <article-title>Precision medicine in 2030&#x2014;seven ways to transform healthcare</article-title>. <source>Cell</source>. (<year>2021</year>) <volume>184</volume>:<fpage>1415</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2021.01.015</pub-id></citation></ref>
<ref id="ref61"><label>61.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marcum</surname> <given-names>JA</given-names></name></person-group>. <article-title>Nutrigenetics/nutrigenomics, personalized nutrition, and precision healthcare</article-title>. <source>Curr Nutr Rep</source>. (<year>2020</year>) <volume>9</volume>:<fpage>338</fpage>&#x2013;<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13668-020-00327-z</pub-id>, PMID: <pub-id pub-id-type="pmid">32578026</pub-id></citation></ref>
<ref id="ref62"><label>62.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dallio</surname> <given-names>M</given-names></name> <name><surname>Romeo</surname> <given-names>M</given-names></name> <name><surname>Gravina</surname> <given-names>AG</given-names></name> <name><surname>Masarone</surname> <given-names>M</given-names></name> <name><surname>Larussa</surname> <given-names>T</given-names></name> <name><surname>Abenavoli</surname> <given-names>L</given-names></name> <etal/></person-group>. <article-title>Nutrigenomics and nutrigenetics in metabolic-(dysfunction) associated fatty liver disease: novel insights and future perspectives</article-title>. <source>Nutrients</source>. (<year>2021</year>) <volume>13</volume>:<fpage>1679</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu13051679</pub-id>, PMID: <pub-id pub-id-type="pmid">34063372</pub-id></citation></ref>
<ref id="ref63"><label>63.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laux</surname> <given-names>L</given-names></name> <name><surname>Blackford</surname> <given-names>R</given-names></name></person-group>. <article-title>The Ketogenic Diet in Dravet Syndrome</article-title>. <source>J Child Neurol</source>. (<year>2013</year>) <volume>28</volume>:<fpage>1041</fpage>&#x2013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0883073813487599</pub-id></citation></ref>
<ref id="ref64"><label>64.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiemer-Kruel</surname> <given-names>A</given-names></name> <name><surname>Haberlandt</surname> <given-names>E</given-names></name> <name><surname>Hartmann</surname> <given-names>H</given-names></name> <name><surname>Wohlrab</surname> <given-names>G</given-names></name> <name><surname>Bast</surname> <given-names>T</given-names></name></person-group>. <article-title>Modified Atkins diet is an effective treatment for children with Doose syndrome</article-title>. <source>Epilepsia</source>. (<year>2017</year>) <volume>58</volume>:<fpage>657</fpage>&#x2013;<lpage>62</lpage>. doi: <pub-id pub-id-type="doi">10.1111/epi.13701</pub-id>, PMID: <pub-id pub-id-type="pmid">28229464</pub-id></citation></ref>
<ref id="ref65"><label>65.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prezioso</surname> <given-names>G</given-names></name> <name><surname>Carlone</surname> <given-names>G</given-names></name> <name><surname>Zaccara</surname> <given-names>G</given-names></name> <name><surname>Verrotti</surname> <given-names>A</given-names></name></person-group>. <article-title>Efficacy of ketogenic diet for infantile spasms: a systematic review</article-title>. <source>Acta Neurol Scand</source>. (<year>2018</year>) <volume>137</volume>:<fpage>4</fpage>&#x2013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ane.12830</pub-id>, PMID: <pub-id pub-id-type="pmid">28875525</pub-id></citation></ref>
<ref id="ref66"><label>66.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname> <given-names>RK</given-names></name> <name><surname>Joshi</surname> <given-names>SM</given-names></name> <name><surname>Potter</surname> <given-names>DM</given-names></name> <name><surname>Leber</surname> <given-names>SM</given-names></name> <name><surname>Carlson</surname> <given-names>MD</given-names></name> <name><surname>Shellhaas</surname> <given-names>RA</given-names></name></person-group>. <article-title>Cognitive outcomes in febrile infection-related epilepsy syndrome treated with the ketogenic diet</article-title>. <source>Pediatrics</source>. (<year>2014</year>) <volume>134</volume>:<fpage>e1431</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1542/peds.2013-3106</pub-id>, PMID: <pub-id pub-id-type="pmid">25332495</pub-id></citation></ref>
<ref id="ref67"><label>67.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname> <given-names>M</given-names></name> <name><surname>Shimono</surname> <given-names>M</given-names></name> <name><surname>Senju</surname> <given-names>A</given-names></name> <name><surname>Kusuhara</surname> <given-names>K</given-names></name> <name><surname>Shiota</surname> <given-names>N</given-names></name></person-group>. <article-title>The ketogenic diet as an effective treatment for Ohtahara syndrome</article-title>. <source>No To Hattatsu</source>. (<year>2011</year>) <volume>43</volume>:<fpage>47</fpage>&#x2013;<lpage>50</lpage>. PMID: <pub-id pub-id-type="pmid">21400932</pub-id></citation></ref>
<ref id="ref68"><label>68.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname> <given-names>TJW</given-names></name> <name><surname>Cervenka</surname> <given-names>MC</given-names></name></person-group>. <article-title>Ketogenic diet therapies for seizures and status epilepticus</article-title>. <source>Semin Neurol</source>. (<year>2020</year>) <volume>40</volume>:<fpage>719</fpage>&#x2013;<lpage>29</lpage>. doi: <pub-id pub-id-type="doi">10.1055/s-0040-1719077</pub-id>, PMID: <pub-id pub-id-type="pmid">33155184</pub-id></citation></ref>
<ref id="ref69"><label>69.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cardinali</surname> <given-names>S</given-names></name> <name><surname>Canafoglia</surname> <given-names>L</given-names></name> <name><surname>Bertoli</surname> <given-names>S</given-names></name> <name><surname>Franceschetti</surname> <given-names>S</given-names></name> <name><surname>Lanzi</surname> <given-names>G</given-names></name> <name><surname>Tagliabue</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>A pilot study of a ketogenic diet in patients with Lafora body disease</article-title>. <source>Epilepsy Res</source>. (<year>2006</year>) <volume>69</volume>:<fpage>129</fpage>&#x2013;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eplepsyres.2006.01.007</pub-id>, PMID: <pub-id pub-id-type="pmid">16504479</pub-id></citation></ref>
<ref id="ref70"><label>70.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname> <given-names>C</given-names></name> <name><surname>Kolbe</surname> <given-names>DL</given-names></name> <name><surname>Mansilla</surname> <given-names>MA</given-names></name> <name><surname>Mason</surname> <given-names>S</given-names></name> <name><surname>Smith</surname> <given-names>RJH</given-names></name> <name><surname>Campbell</surname> <given-names>CA</given-names></name></person-group>. <article-title>Ketogenic diet &#x2013; a novel treatment for early epileptic encephalopathy due to PIGA deficiency</article-title>. <source>Brain Dev</source>. (<year>2016</year>) <volume>38</volume>:<fpage>848</fpage>&#x2013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.braindev.2016.04.004</pub-id>, PMID: <pub-id pub-id-type="pmid">27126216</pub-id></citation></ref>
<ref id="ref71"><label>71.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lefevre</surname> <given-names>F</given-names></name> <name><surname>Aronson</surname> <given-names>N</given-names></name></person-group>. <article-title>Ketogenic diet for the treatment of refractory epilepsy in children: a systematic review of efficacy</article-title>. <source>Pediatrics</source>. (<year>2000</year>) <volume>105</volume>:<fpage>e46-e</fpage>. doi: <pub-id pub-id-type="doi">10.1542/peds.105.4.e46</pub-id></citation></ref>
<ref id="ref72"><label>72.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname> <given-names>J</given-names></name> <name><surname>Khedekar Kale</surname> <given-names>D</given-names></name> <name><surname>Naik</surname> <given-names>VD</given-names></name> <name><surname>Thakker</surname> <given-names>F</given-names></name> <name><surname>Bailur</surname> <given-names>S</given-names></name></person-group>. <article-title>Substantial remission in subacute Sclerosing Panencephalitis by following the ketogenic diet: a case report</article-title>. <source>Cureus</source>. (<year>2019</year>) <volume>11</volume>:<fpage>e5485</fpage>. doi: <pub-id pub-id-type="doi">10.7759/cureus.5485</pub-id>, PMID: <pub-id pub-id-type="pmid">31489275</pub-id></citation></ref>
<ref id="ref73"><label>73.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jurecka</surname> <given-names>A</given-names></name> <name><surname>Opoka-Winiarska</surname> <given-names>V</given-names></name> <name><surname>Rokicki</surname> <given-names>D</given-names></name> <name><surname>Tylki-Szyma&#x0144;ska</surname> <given-names>A</given-names></name></person-group>. <article-title>Neurologic presentation, diagnostics, and therapeutic insights in a severe case of adenylosuccinate lyase deficiency</article-title>. <source>J Child Neurol</source>. (<year>2012</year>) <volume>27</volume>:<fpage>645</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0883073811424465</pub-id></citation></ref>
<ref id="ref74"><label>74.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kossoff</surname> <given-names>EH</given-names></name> <name><surname>Henry</surname> <given-names>BJ</given-names></name> <name><surname>Cervenka</surname> <given-names>MC</given-names></name></person-group>. <article-title>Efficacy of dietary therapy for juvenile myoclonic epilepsy</article-title>. <source>Epilepsy Behav</source>. (<year>2013</year>) <volume>26</volume>:<fpage>162</fpage>&#x2013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.yebeh.2012.11.007</pub-id>, PMID: <pub-id pub-id-type="pmid">23266114</pub-id></citation></ref>
<ref id="ref75"><label>75.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>M&#x00FC;ller</surname> <given-names>A</given-names></name> <name><surname>Helbig</surname> <given-names>I</given-names></name> <name><surname>Jansen</surname> <given-names>C</given-names></name> <name><surname>Bast</surname> <given-names>T</given-names></name> <name><surname>Guerrini</surname> <given-names>R</given-names></name> <name><surname>J&#x00E4;hn</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy</article-title>. <source>Eur J Paediatr Neurol</source>. (<year>2016</year>) <volume>20</volume>:<fpage>147</fpage>&#x2013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejpn.2015.09.001</pub-id>, PMID: <pub-id pub-id-type="pmid">26387070</pub-id></citation></ref>
<ref id="ref76"><label>76.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Madaan</surname> <given-names>P</given-names></name> <name><surname>Jauhari</surname> <given-names>P</given-names></name> <name><surname>Chakrabarty</surname> <given-names>B</given-names></name> <name><surname>Gulati</surname> <given-names>S</given-names></name></person-group>. <article-title>Ketogenic diet in epilepsy of infancy with migrating focal seizures</article-title>. <source>Pediatr Neurol</source>. (<year>2019</year>) <volume>95</volume>:<fpage>92</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2018.12.019</pub-id>, PMID: <pub-id pub-id-type="pmid">30704868</pub-id></citation></ref>
<ref id="ref77"><label>77.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clemens</surname> <given-names>Z</given-names></name> <name><surname>Kelemen</surname> <given-names>A</given-names></name> <name><surname>Fogarasi</surname> <given-names>A</given-names></name> <name><surname>T&#x00F3;th</surname> <given-names>C</given-names></name></person-group>. <article-title>Childhood absence epilepsy successfully treated with the Paleolithic ketogenic diet</article-title>. <source>Neurol Ther</source>. (<year>2013</year>) <volume>2</volume>:<fpage>71</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40120-013-0013-2</pub-id>, PMID: <pub-id pub-id-type="pmid">26000218</pub-id></citation></ref>
<ref id="ref78"><label>78.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ville</surname> <given-names>D</given-names></name> <name><surname>Chiron</surname> <given-names>C</given-names></name> <name><surname>Laschet</surname> <given-names>J</given-names></name> <name><surname>Dulac</surname> <given-names>O</given-names></name></person-group>. <article-title>The ketogenic diet can be used successfully in combination with corticosteroids for epileptic encephalopathies</article-title>. <source>Epilepsy Behav</source>. (<year>2015</year>) <volume>48</volume>:<fpage>61</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.yebeh.2015.03.003</pub-id>, PMID: <pub-id pub-id-type="pmid">26057351</pub-id></citation></ref>
<ref id="ref79"><label>79.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thijs</surname> <given-names>RD</given-names></name> <name><surname>Surges</surname> <given-names>R</given-names></name> <name><surname>O'Brien</surname> <given-names>TJ</given-names></name> <name><surname>Sander</surname> <given-names>JW</given-names></name></person-group>. <article-title>Epilepsy in adults</article-title>. <source>Lancet</source>. (<year>2019</year>) <volume>393</volume>:<fpage>689</fpage>&#x2013;<lpage>701</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(18)32596-0</pub-id></citation></ref>
<ref id="ref80"><label>80.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anwar</surname> <given-names>H</given-names></name> <name><surname>Khan</surname> <given-names>QU</given-names></name> <name><surname>Nadeem</surname> <given-names>N</given-names></name> <name><surname>Pervaiz</surname> <given-names>I</given-names></name> <name><surname>Ali</surname> <given-names>M</given-names></name> <name><surname>Cheema</surname> <given-names>FF</given-names></name></person-group>. <article-title>Epileptic seizures</article-title>. <source>Discoveries (Craiova, Romania)</source>. (<year>2020</year>) <volume>8</volume>:<fpage>e110</fpage>. doi: <pub-id pub-id-type="doi">10.15190/d.2020.7</pub-id>, PMID: <pub-id pub-id-type="pmid">32577498</pub-id></citation></ref>
<ref id="ref81"><label>81.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zarnowska</surname> <given-names>IM</given-names></name></person-group>. <article-title>Therapeutic use of the ketogenic diet in refractory epilepsy: what we know and what still needs to be learned</article-title>. <source>Nutrients</source>. (<year>2020</year>) <volume>12</volume>:<fpage>2616</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu12092616</pub-id>, PMID: <pub-id pub-id-type="pmid">32867258</pub-id></citation></ref>
<ref id="ref82"><label>82.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>D</given-names></name> <name><surname>Liu</surname> <given-names>Y</given-names></name> <name><surname>Fan</surname> <given-names>L</given-names></name> <name><surname>Yang</surname> <given-names>H</given-names></name> <name><surname>Pan</surname> <given-names>M</given-names></name> <name><surname>Shi</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Improvement on BAF53B mutation caused developmental and epileptic encephalopathy with a ketogenic diet</article-title>. <source>J Food Nutr Res</source>. (<year>2022</year>) <volume>5</volume>:<fpage>712</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.26502/jfsnr.2642-110000118</pub-id></citation></ref>
<ref id="ref83"><label>83.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prasoppokakorn</surname> <given-names>T</given-names></name> <name><surname>Jirasakuldej</surname> <given-names>S</given-names></name> <name><surname>Lakananurak</surname> <given-names>N</given-names></name></person-group>. <article-title>Medium-chain triglyceride ketogenic diet is effective for treatment of an adult with super-refractory status epilepticus: a case report and literature review</article-title>. <source>Eur J Clin Nutr</source>. (<year>2019</year>) <volume>73</volume>:<fpage>1594</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41430-019-0471-4</pub-id></citation></ref>
<ref id="ref84"><label>84.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bekker</surname> <given-names>YAC</given-names></name> <name><surname>Lambrechts</surname> <given-names>DA</given-names></name> <name><surname>Verhoeven</surname> <given-names>JS</given-names></name> <name><surname>van Boxtel</surname> <given-names>J</given-names></name> <name><surname>Troost</surname> <given-names>C</given-names></name> <name><surname>Kamsteeg</surname> <given-names>E-J</given-names></name> <etal/></person-group>. <article-title>Failure of ketogenic diet therapy in GLUT1 deficiency syndrome</article-title>. <source>Eur J Paediatr Neurol</source>. (<year>2019</year>) <volume>23</volume>:<fpage>404</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejpn.2019.02.012</pub-id>, PMID: <pub-id pub-id-type="pmid">30885501</pub-id></citation></ref>
<ref id="ref85"><label>85.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sisodiya</surname> <given-names>SM</given-names></name></person-group>. <article-title>Epilepsy genetics and the precision medicine matrix</article-title>. <source>Lancet Neurol</source>. (<year>2020</year>) <volume>19</volume>:<fpage>29</fpage>&#x2013;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(19)30331-X</pub-id>, PMID: <pub-id pub-id-type="pmid">31494010</pub-id></citation></ref>
<ref id="ref86"><label>86.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neal</surname> <given-names>EG</given-names></name> <name><surname>Chaffe</surname> <given-names>H</given-names></name> <name><surname>Schwartz</surname> <given-names>RH</given-names></name> <name><surname>Lawson</surname> <given-names>MS</given-names></name> <name><surname>Edwards</surname> <given-names>N</given-names></name> <name><surname>Fitzsimmons</surname> <given-names>G</given-names></name> <etal/></person-group>. <article-title>The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial</article-title>. <source>Lancet Neurol</source>. (<year>2008</year>) <volume>7</volume>:<fpage>500</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(08)70092-9</pub-id>, PMID: <pub-id pub-id-type="pmid">18456557</pub-id></citation></ref>
<ref id="ref87"><label>87.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname> <given-names>MP</given-names></name> <name><surname>Banka</surname> <given-names>S</given-names></name> <name><surname>Bjornsson</surname> <given-names>HT</given-names></name> <name><surname>Bodamer</surname> <given-names>O</given-names></name> <name><surname>Chudley</surname> <given-names>AE</given-names></name> <name><surname>Harris</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Kabuki syndrome: international consensus diagnostic criteria</article-title>. <source>J Med Genet</source>. (<year>2019</year>) <volume>56</volume>:<fpage>89</fpage>&#x2013;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jmedgenet-2018-105625</pub-id>, PMID: <pub-id pub-id-type="pmid">30514738</pub-id></citation></ref>
<ref id="ref88"><label>88.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benjamin</surname> <given-names>JS</given-names></name> <name><surname>Pilarowski</surname> <given-names>GO</given-names></name> <name><surname>Carosso</surname> <given-names>GA</given-names></name> <name><surname>Zhang</surname> <given-names>L</given-names></name> <name><surname>Huso</surname> <given-names>DL</given-names></name> <name><surname>Goff</surname> <given-names>LA</given-names></name> <etal/></person-group>. <article-title>A ketogenic diet rescues hippocampal memory defects in a mouse model of kabuki syndrome</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2017</year>) <volume>114</volume>:<fpage>125</fpage>&#x2013;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1611431114</pub-id></citation></ref>
<ref id="ref89"><label>89.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname> <given-names>S</given-names></name> <name><surname>Soliven</surname> <given-names>M</given-names></name> <name><surname>Poff</surname> <given-names>A</given-names></name> <name><surname>D&#x2019;Agostino</surname> <given-names>D</given-names></name></person-group>. <article-title>Using exogenous &#x03B2;HB as an epigenetic modifier to mitigate the symptoms of kabuki syndrome</article-title>. <source>FASEB J</source>. (<year>2020</year>) <volume>34</volume>:<fpage>1</fpage>. doi: <pub-id pub-id-type="doi">10.1096/fasebj.2020.34.s1.06268</pub-id></citation></ref>
<ref id="ref90"><label>90.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname> <given-names>RR</given-names></name> <name><surname>Bird</surname> <given-names>AP</given-names></name></person-group>. <article-title>MeCP2 mutations: progress towards understanding and treating Rett syndrome</article-title>. <source>Genome Med</source>. (<year>2017</year>) <volume>9</volume>:<fpage>17</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13073-017-0411-7</pub-id>, PMID: <pub-id pub-id-type="pmid">28212680</pub-id></citation></ref>
<ref id="ref91"><label>91.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liebhaber</surname> <given-names>GM</given-names></name> <name><surname>Riemann</surname> <given-names>E</given-names></name> <name><surname>Matthias Baumeister</surname> <given-names>FA</given-names></name></person-group>. <article-title>Ketogenic diet in Rett syndrome</article-title>. <source>J Child Neurol</source>. (<year>2003</year>) <volume>18</volume>:<fpage>74</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1177/08830738030180011801</pub-id></citation></ref>
<ref id="ref92"><label>92.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciarlone</surname> <given-names>SL</given-names></name> <name><surname>Grieco</surname> <given-names>JC</given-names></name> <name><surname>D'Agostino</surname> <given-names>DP</given-names></name> <name><surname>Weeber</surname> <given-names>EJ</given-names></name></person-group>. <article-title>Ketone ester supplementation attenuates seizure activity, and improves behavior and hippocampal synaptic plasticity in an Angelman syndrome mouse model</article-title>. <source>Neurobiol Dis</source>. (<year>2016</year>) <volume>96</volume>:<fpage>38</fpage>&#x2013;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2016.08.002</pub-id></citation></ref>
<ref id="ref93"><label>93.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herber</surname> <given-names>DL</given-names></name> <name><surname>Weeber</surname> <given-names>EJ</given-names></name> <name><surname>D&#x2019;Agostino</surname> <given-names>DP</given-names></name> <name><surname>Duis</surname> <given-names>J</given-names></name></person-group>. <article-title>Evaluation of the safety and tolerability of a nutritional formulation in patients with ANgelman syndrome (FANS): study protocol for a randomized controlled trial</article-title>. <source>Trials</source>. (<year>2020</year>) <volume>21</volume>:<fpage>60</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13063-019-3996-x</pub-id>, PMID: <pub-id pub-id-type="pmid">31918761</pub-id></citation></ref>
<ref id="ref94"><label>94.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Operto</surname> <given-names>F</given-names></name> <name><surname>Matricardi</surname> <given-names>S</given-names></name> <name><surname>Pastorino</surname> <given-names>GMG</given-names></name> <name><surname>Verrotti</surname> <given-names>A</given-names></name> <name><surname>Coppola</surname> <given-names>G</given-names></name></person-group>. <article-title>The ketogenic diet for the treatment of mood disorders in comorbidity with epilepsy in children and adolescents</article-title>. <source>J Child Neurol</source>. (<year>2020</year>) <volume>11</volume>:<fpage>74</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2020.578396</pub-id></citation></ref>
<ref id="ref95"><label>95.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ari</surname> <given-names>C</given-names></name> <name><surname>Kov&#x00E1;cs</surname> <given-names>Z</given-names></name> <name><surname>Juhasz</surname> <given-names>G</given-names></name> <name><surname>Murdun</surname> <given-names>C</given-names></name> <name><surname>Goldhagen</surname> <given-names>CR</given-names></name> <name><surname>Koutnik</surname> <given-names>AP</given-names></name> <etal/></person-group>. <article-title>Corrigendum: exogenous ketone supplements reduce anxiety-related behavior in Sprague-Dawley and Wistar albino Glaxo/Rijswijk rats</article-title>. <source>Front Mol Neurosci</source>. (<year>2017</year>) <volume>10</volume>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2017.00036</pub-id>, PMID: <pub-id pub-id-type="pmid">28210213</pub-id></citation></ref>
<ref id="ref96"><label>96.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname> <given-names>IH</given-names></name> <name><surname>Campbell</surname> <given-names>H</given-names></name></person-group>. <article-title>Ketosis and bipolar disorder: controlled analytic study of online reports</article-title>. <source>BJPsych Open</source>. (<year>2019</year>) <volume>5</volume>:<fpage>e58</fpage>. doi: <pub-id pub-id-type="doi">10.1192/bjo.2019.49</pub-id>, PMID: <pub-id pub-id-type="pmid">31530294</pub-id></citation></ref>
<ref id="ref97"><label>97.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kraeuter</surname> <given-names>A-K</given-names></name> <name><surname>Phillips</surname> <given-names>R</given-names></name> <name><surname>Sarnyai</surname> <given-names>Z</given-names></name></person-group>. <article-title>Ketogenic therapy in neurodegenerative and psychiatric disorders: from mice to men</article-title>. <source>Prog Neuro-Psychopharmacol Biol Psychiatry</source>. (<year>2020</year>) <volume>101</volume>:<fpage>109913</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pnpbp.2020.109913</pub-id>, PMID: <pub-id pub-id-type="pmid">32151695</pub-id></citation></ref>
<ref id="ref98"><label>98.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niepoetter</surname> <given-names>P</given-names></name> <name><surname>Gopalan</surname> <given-names>C</given-names></name></person-group>. <article-title>The effects of ketogenic diets on psychiatric disorders involving mitochondrial dysfunction: a literature review of the influence of dieting on autism, depression, anxiety, and schizophrenia</article-title>. <source>HAPS Educator</source>. (<year>2019</year>) <volume>23</volume>:<fpage>426</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.21692/haps.2019.002</pub-id></citation></ref>
<ref id="ref99"><label>99.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bostock</surname> <given-names>ECS</given-names></name> <name><surname>Kirkby</surname> <given-names>KC</given-names></name> <name><surname>BVM</surname> <given-names>T</given-names></name></person-group>. <article-title>The current status of the ketogenic diet in psychiatry</article-title>. <source>Front Psychiatry</source>. (<year>2017</year>) <volume>8</volume>:<fpage>43</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fpsyt.2017.00043</pub-id>, PMID: <pub-id pub-id-type="pmid">28373848</pub-id></citation></ref>
<ref id="ref100"><label>100.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kov&#x00E1;cs</surname> <given-names>Z</given-names></name> <name><surname>D&#x2019;Agostino</surname> <given-names>DP</given-names></name> <name><surname>Diamond</surname> <given-names>D</given-names></name> <name><surname>Kindy</surname> <given-names>MS</given-names></name> <name><surname>Rogers</surname> <given-names>C</given-names></name> <name><surname>Ari</surname> <given-names>C</given-names></name></person-group>. <article-title>Therapeutic potential of exogenous ketone supplement induced ketosis in the treatment of psychiatric disorders</article-title>. <source>Front Psychiatry</source>. (<year>2019</year>) <volume>10</volume>:<fpage>363</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fpsyt.2019.00363</pub-id>, PMID: <pub-id pub-id-type="pmid">31178772</pub-id></citation></ref>
<ref id="ref101"><label>101.</label> <citation citation-type="book"><person-group person-group-type="author"><name><surname>Soria Lopez</surname> <given-names>JA</given-names></name> <name><surname>Gonz&#x00E1;lez</surname> <given-names>HM</given-names></name> <name><surname>L&#x00E9;ger</surname> <given-names>GC</given-names></name></person-group>. <article-title>Chapter 13- Alzheimer's disease</article-title> In: <person-group person-group-type="editor"><name><surname>Dekosky</surname> <given-names>ST</given-names></name> <name><surname>Asthana</surname> <given-names>S</given-names></name></person-group>, editors. <source>Handbook of clinical neurology</source>. <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name> (<year>2019</year>)</citation></ref>
<ref id="ref102"><label>102.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frazier</surname> <given-names>HN</given-names></name> <name><surname>Ghoweri</surname> <given-names>AO</given-names></name> <name><surname>Anderson</surname> <given-names>KL</given-names></name> <name><surname>Lin</surname> <given-names>R-L</given-names></name> <name><surname>Porter</surname> <given-names>NM</given-names></name> <name><surname>Thibault</surname> <given-names>O</given-names></name></person-group>. <article-title>Broadening the definition of brain insulin resistance in aging and Alzheimer's disease</article-title>. <source>Exp Neurol</source>. (<year>2019</year>) <volume>313</volume>:<fpage>79</fpage>&#x2013;<lpage>87</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.expneurol.2018.12.007</pub-id>, PMID: <pub-id pub-id-type="pmid">30576640</pub-id></citation></ref>
<ref id="ref103"><label>103.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hertz</surname> <given-names>L</given-names></name> <name><surname>Chen</surname> <given-names>Y</given-names></name> <name><surname>Waagepetersen</surname> <given-names>HS</given-names></name></person-group>. <article-title>Effects of ketone bodies in Alzheimer's disease in relation to neural hypometabolism, &#x03B2;-amyloid toxicity, and astrocyte function</article-title>. <source>J Neurochem</source>. (<year>2015</year>) <volume>134</volume>:<fpage>7</fpage>&#x2013;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jnc.13107</pub-id>, PMID: <pub-id pub-id-type="pmid">25832906</pub-id></citation></ref>
<ref id="ref104"><label>104.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kashiwaya</surname> <given-names>Y</given-names></name> <name><surname>Bergman</surname> <given-names>C</given-names></name> <name><surname>Lee</surname> <given-names>J-H</given-names></name> <name><surname>Wan</surname> <given-names>R</given-names></name> <name><surname>King</surname> <given-names>MT</given-names></name> <name><surname>Mughal</surname> <given-names>MR</given-names></name> <etal/></person-group>. <article-title>A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease</article-title>. <source>Neurobiol Aging</source>. (<year>2013</year>) <volume>34</volume>:<fpage>1530</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2012.11.023</pub-id></citation></ref>
<ref id="ref105"><label>105.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pawlosky</surname> <given-names>RJ</given-names></name> <name><surname>Kashiwaya</surname> <given-names>Y</given-names></name> <name><surname>King</surname> <given-names>MT</given-names></name> <name><surname>Veech</surname> <given-names>RL</given-names></name></person-group>. <article-title>A dietary ketone Ester normalizes abnormal behavior in a mouse model of Alzheimer&#x2019;s disease</article-title>. <source>Int J Mol Sci</source>. (<year>2020</year>) <volume>21</volume>:<fpage>1044</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21031044</pub-id>, PMID: <pub-id pub-id-type="pmid">32033248</pub-id></citation></ref>
<ref id="ref106"><label>106.</label> <citation citation-type="book"><person-group person-group-type="author"><name><surname>Kapogiannis</surname> <given-names>D</given-names></name> <name><surname>Avgerinos</surname> <given-names>KI</given-names></name></person-group>. <article-title>Chapter three-brain glucose and ketone utilization in brain aging and neurodegenerative diseases</article-title> In: <person-group person-group-type="editor"><name><surname>S&#x00F6;derbom</surname> <given-names>G</given-names></name> <name><surname>Esterline</surname> <given-names>R</given-names></name> <name><surname>Oscarsson</surname> <given-names>J</given-names></name> <name><surname>Mattson</surname> <given-names>MP</given-names></name></person-group>, editors. <source>International review of neurobiology</source>. <publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>Academic Press</publisher-name> (<year>2020</year>)</citation></ref>
<ref id="ref107"><label>107.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Broom</surname> <given-names>GM</given-names></name> <name><surname>Shaw</surname> <given-names>IC</given-names></name> <name><surname>Rucklidge</surname> <given-names>JJ</given-names></name></person-group>. <article-title>The ketogenic diet as a potential treatment and prevention strategy for Alzheimer's disease</article-title>. <source>Nutrition</source>. (<year>2019</year>) <volume>60</volume>:<fpage>118</fpage>&#x2013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nut.2018.10.003</pub-id>, PMID: <pub-id pub-id-type="pmid">30554068</pub-id></citation></ref>
<ref id="ref108"><label>108.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uddin</surname> <given-names>MS</given-names></name> <name><surname>Kabir</surname> <given-names>MT</given-names></name> <name><surname>Tewari</surname> <given-names>D</given-names></name> <name><surname>Al Mamun</surname> <given-names>A</given-names></name> <name><surname>Barreto</surname> <given-names>GE</given-names></name> <name><surname>Bungau</surname> <given-names>SG</given-names></name> <etal/></person-group>. <article-title>Emerging therapeutic promise of ketogenic diet to attenuate neuropathological alterations in Alzheimer&#x2019;s disease</article-title>. <source>Mol Neurobiol</source>. (<year>2020</year>) <volume>57</volume>:<fpage>4961</fpage>&#x2013;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-020-02065-3</pub-id>, PMID: <pub-id pub-id-type="pmid">32820459</pub-id></citation></ref>
<ref id="ref109"><label>109.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname> <given-names>ST</given-names></name> <name><surname>Vogel</surname> <given-names>JL</given-names></name> <name><surname>Barr</surname> <given-names>LJ</given-names></name> <name><surname>Garvin</surname> <given-names>F</given-names></name> <name><surname>Jones</surname> <given-names>JJ</given-names></name> <name><surname>Costantini</surname> <given-names>LC</given-names></name></person-group>. <article-title>Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial</article-title>. <source>Nutr Metab (Lond)</source>. (<year>2009</year>) <volume>6</volume>:<fpage>31</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1743-7075-6-31</pub-id>, PMID: <pub-id pub-id-type="pmid">19664276</pub-id></citation></ref>
<ref id="ref110"><label>110.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Itallie</surname> <given-names>TB</given-names></name> <name><surname>Nonas</surname> <given-names>C</given-names></name> <name><surname>Di Rocco</surname> <given-names>A</given-names></name> <name><surname>Boyar</surname> <given-names>K</given-names></name> <name><surname>Hyams</surname> <given-names>K</given-names></name> <name><surname>Heymsfield</surname> <given-names>SB</given-names></name></person-group>. <article-title>Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study</article-title>. <source>Neurology</source>. (<year>2005</year>) <volume>64</volume>:<fpage>728</fpage>&#x2013;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1212/01.WNL.0000152046.11390.45</pub-id>, PMID: <pub-id pub-id-type="pmid">15728303</pub-id></citation></ref>
<ref id="ref111"><label>111.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chia</surname> <given-names>SJ</given-names></name> <name><surname>Tan</surname> <given-names>E-K</given-names></name> <name><surname>Chao</surname> <given-names>Y-X</given-names></name></person-group>. <article-title>Historical perspective: models of Parkinson&#x2019;s disease</article-title>. <source>Int J Mol Sci</source>. (<year>2020</year>) <volume>21</volume>:<fpage>2464</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21072464</pub-id>, PMID: <pub-id pub-id-type="pmid">32252301</pub-id></citation></ref>
<ref id="ref112"><label>112.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tieu</surname> <given-names>K</given-names></name> <name><surname>Perier</surname> <given-names>C</given-names></name> <name><surname>Caspersen</surname> <given-names>C</given-names></name> <name><surname>Teismann</surname> <given-names>P</given-names></name> <name><surname>Wu</surname> <given-names>DC</given-names></name> <name><surname>Yan</surname> <given-names>SD</given-names></name> <etal/></person-group>. <article-title>D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease</article-title>. <source>J Clin Invest</source>. (<year>2003</year>) <volume>112</volume>:<fpage>892</fpage>&#x2013;<lpage>901</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI200318797</pub-id>, PMID: <pub-id pub-id-type="pmid">12975474</pub-id></citation></ref>
<ref id="ref113"><label>113.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cornille</surname> <given-names>E</given-names></name> <name><surname>Abou-Hamdan</surname> <given-names>M</given-names></name> <name><surname>Khrestchatisky</surname> <given-names>M</given-names></name> <name><surname>Nieoullon</surname> <given-names>A</given-names></name> <name><surname>de Reggi</surname> <given-names>M</given-names></name> <name><surname>Gharib</surname> <given-names>B</given-names></name></person-group>. <article-title>Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine</article-title>. <source>Neuroscience</source>. (<year>2010</year>) <volume>11</volume>:<fpage>51</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2202-11-51</pub-id>, PMID: <pub-id pub-id-type="pmid">20416081</pub-id></citation></ref>
<ref id="ref114"><label>114.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname> <given-names>MCL</given-names></name> <name><surname>Murtagh</surname> <given-names>DKJ</given-names></name> <name><surname>Gilbertson</surname> <given-names>LJ</given-names></name> <name><surname>Asztely</surname> <given-names>FJS</given-names></name> <name><surname>Lynch</surname> <given-names>CDP</given-names></name></person-group>. <article-title>Low-fat versus ketogenic diet in Parkinson's disease: a pilot randomized controlled trial</article-title>. <source>Mov Disord</source>. (<year>2018</year>) <volume>33</volume>:<fpage>1306</fpage>&#x2013;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.27390</pub-id>, PMID: <pub-id pub-id-type="pmid">30098269</pub-id></citation></ref>
<ref id="ref115"><label>115.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fath</surname> <given-names>MA</given-names></name> <name><surname>Ahmad</surname> <given-names>IM</given-names></name> <name><surname>Smith</surname> <given-names>CJ</given-names></name> <name><surname>Spence</surname> <given-names>J</given-names></name> <name><surname>Spitz</surname> <given-names>DR</given-names></name></person-group>. <article-title>Enhancement of carboplatin-mediated lung Cancer cell killing by simultaneous disruption of glutathione and Thioredoxin metabolism</article-title>. <source>Clin Cancer Res</source>. (<year>2011</year>) <volume>17</volume>:<fpage>6206</fpage>&#x2013;<lpage>17</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-0736</pub-id>, PMID: <pub-id pub-id-type="pmid">21844013</pub-id></citation></ref>
<ref id="ref116"><label>116.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poff</surname> <given-names>AM</given-names></name> <name><surname>Ari</surname> <given-names>C</given-names></name> <name><surname>Arnold</surname> <given-names>P</given-names></name> <name><surname>Seyfried</surname> <given-names>TN</given-names></name> <name><surname>D'Agostino</surname> <given-names>DP</given-names></name></person-group>. <article-title>Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer</article-title>. <source>Int J Cancer</source>. (<year>2014</year>) <volume>135</volume>:<fpage>1711</fpage>&#x2013;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ijc.28809</pub-id>, PMID: <pub-id pub-id-type="pmid">24615175</pub-id></citation></ref>
<ref id="ref117"><label>117.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dal Bello</surname> <given-names>S</given-names></name> <name><surname>Valdemarin</surname> <given-names>F</given-names></name> <name><surname>Martinuzzi</surname> <given-names>D</given-names></name> <name><surname>Filippi</surname> <given-names>F</given-names></name> <name><surname>Gigli</surname> <given-names>GL</given-names></name> <name><surname>Valente</surname> <given-names>M</given-names></name></person-group>. <article-title>Ketogenic diet in the treatment of gliomas and glioblastomas</article-title>. <source>Nutrients</source>. (<year>2022</year>) <volume>14</volume>:<fpage>3851</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu14183851</pub-id>, PMID: <pub-id pub-id-type="pmid">36145228</pub-id></citation></ref>
<ref id="ref118"><label>118.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>K&#x00E4;mmerer</surname> <given-names>U</given-names></name> <name><surname>Klement</surname> <given-names>RJ</given-names></name> <name><surname>Joos</surname> <given-names>FT</given-names></name> <name><surname>S&#x00FC;tterlin</surname> <given-names>M</given-names></name> <name><surname>Reuss-Borst</surname> <given-names>M</given-names></name></person-group>. <article-title>Low carb and ketogenic diets increase quality of life, physical performance, body composition, and metabolic health of women with breast cancer</article-title>. <source>Nutrients</source>. (<year>2021</year>) <volume>13</volume>:<fpage>1029</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu13031029</pub-id></citation></ref>
<ref id="ref119"><label>119.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Y-F</given-names></name> <name><surname>Mattamel</surname> <given-names>PB</given-names></name> <name><surname>Joseph</surname> <given-names>T</given-names></name> <name><surname>Huang</surname> <given-names>J</given-names></name> <name><surname>Chen</surname> <given-names>Q</given-names></name> <name><surname>Akinwunmi</surname> <given-names>BO</given-names></name> <etal/></person-group>. <article-title>Efficacy of low-carbohydrate ketogenic diet as an adjuvant Cancer therapy: a systematic review and Meta-analysis of randomized controlled trials</article-title>. <source>Nutrients</source>. (<year>2021</year>) <volume>13</volume>:<fpage>1388</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu13051388</pub-id>, PMID: <pub-id pub-id-type="pmid">33918992</pub-id></citation></ref>
<ref id="ref120"><label>120.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname> <given-names>C</given-names></name> <name><surname>Kaemmerer</surname> <given-names>U</given-names></name> <name><surname>Illert</surname> <given-names>B</given-names></name> <name><surname>Muehling</surname> <given-names>B</given-names></name> <name><surname>Pfetzer</surname> <given-names>N</given-names></name> <name><surname>Wittig</surname> <given-names>R</given-names></name> <etal/></person-group>. <article-title>Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides</article-title>. <source>BMC Cancer</source>. (<year>2008</year>) <volume>8</volume>:<fpage>122</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2407-8-122</pub-id>, PMID: <pub-id pub-id-type="pmid">18447912</pub-id></citation></ref>
<ref id="ref121"><label>121.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Houten</surname> <given-names>SM</given-names></name> <name><surname>Violante</surname> <given-names>S</given-names></name> <name><surname>Ventura</surname> <given-names>FV</given-names></name> <name><surname>Wanders</surname> <given-names>RJA</given-names></name></person-group>. <article-title>The biochemistry and physiology of mitochondrial fatty acid &#x03B2;-oxidation and its genetic disorders</article-title>. <source>Annu Rev Physiol</source>. (<year>2016</year>) <volume>78</volume>:<fpage>23</fpage>&#x2013;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-physiol-021115-105045</pub-id>, PMID: <pub-id pub-id-type="pmid">26474213</pub-id></citation></ref>
<ref id="ref122"><label>122.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindquist</surname> <given-names>C</given-names></name> <name><surname>Bj&#x00F8;rndal</surname> <given-names>B</given-names></name> <name><surname>Rossmann</surname> <given-names>CR</given-names></name> <name><surname>Svardal</surname> <given-names>A</given-names></name> <name><surname>Hallstr&#x00F6;m</surname> <given-names>S</given-names></name> <name><surname>Berge</surname> <given-names>RK</given-names></name></person-group>. <article-title>A fatty acid analogue targeting mitochondria exerts a plasma triacylglycerol lowering effect in rats with impaired carnitine biosynthesis</article-title>. <source>PloS one</source>. (<year>2018</year>) <volume>13</volume>:<fpage>e0194978</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0194978</pub-id>, PMID: <pub-id pub-id-type="pmid">29590220</pub-id></citation></ref>
<ref id="ref123"><label>123.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mooli</surname> <given-names>RGR</given-names></name> <name><surname>Ramakrishnan</surname> <given-names>SK</given-names></name></person-group>. <article-title>Emerging role of hepatic Ketogenesis in fatty liver disease</article-title>. <source>Front Physiol</source>. (<year>2022</year>) <volume>13</volume>:<fpage>946474</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphys.2022.946474</pub-id>, PMID: <pub-id pub-id-type="pmid">35860662</pub-id></citation></ref>
<ref id="ref124"><label>124.</label> <citation citation-type="book"><person-group person-group-type="author"><name><surname>Ferreira</surname> <given-names>CR</given-names></name> <name><surname>van Karnebeek</surname> <given-names>CDM</given-names></name></person-group>. <article-title>Chapter 22- inborn errors of metabolism</article-title>. In: <person-group person-group-type="editor"><name><surname>Vries</surname> <given-names>LS</given-names> <prefix>de</prefix></name> <name><surname>Glass</surname> <given-names>HC</given-names></name></person-group>, <source>Handbook of clinical neurology</source>: <publisher-name>Elsevier</publisher-name>; <publisher-loc>Amsterdam</publisher-loc> (<year>2019</year>)</citation></ref>
<ref id="ref125"><label>125.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Lorenzo</surname> <given-names>C</given-names></name> <name><surname>Ballerini</surname> <given-names>G</given-names></name> <name><surname>Barbanti</surname> <given-names>P</given-names></name> <name><surname>Bernardini</surname> <given-names>A</given-names></name> <name><surname>D&#x2019;arrigo</surname> <given-names>G</given-names></name> <name><surname>Egeo</surname> <given-names>G</given-names></name> <etal/></person-group>. <article-title>Applications of ketogenic diets in patients with headache: clinical recommendations</article-title>. <source>Nutrients</source>. (<year>2021</year>) <volume>13</volume>:<fpage>2307</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu13072307</pub-id>, PMID: <pub-id pub-id-type="pmid">34371817</pub-id></citation></ref>
<ref id="ref126"><label>126.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>J</given-names></name> <name><surname>Ren</surname> <given-names>C</given-names></name> <name><surname>Dong</surname> <given-names>Y</given-names></name> <name><surname>Wali</surname> <given-names>JA</given-names></name> <name><surname>Song</surname> <given-names>H</given-names></name> <name><surname>Zhang</surname> <given-names>Y</given-names></name> <etal/></person-group>. <article-title>Ketogenic diet combined with moderate aerobic exercise training ameliorates white adipose tissue mass, serum biomarkers, and hepatic lipid metabolism in high-fat diet-induced obese mice</article-title>. <source>Nutrients</source>. (<year>2023</year>) <volume>15</volume>:<fpage>251</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu15010251</pub-id>, PMID: <pub-id pub-id-type="pmid">36615908</pub-id></citation></ref>
<ref id="ref127"><label>127.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Batch</surname> <given-names>JT</given-names></name> <name><surname>Lamsal</surname> <given-names>SP</given-names></name> <name><surname>Adkins</surname> <given-names>M</given-names></name> <name><surname>Sultan</surname> <given-names>S</given-names></name> <name><surname>Ramirez</surname> <given-names>MN</given-names></name></person-group>. <article-title>Advantages and disadvantages of the ketogenic diet: a review article</article-title>. <source>Cureus</source>. (<year>2020</year>) <volume>12</volume>:<fpage>e9639</fpage>. doi: <pub-id pub-id-type="doi">10.7759/cureus.9639</pub-id>, PMID: <pub-id pub-id-type="pmid">32923239</pub-id></citation></ref>
<ref id="ref128"><label>128.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanner</surname> <given-names>HL</given-names></name> <name><surname>Dekker Nitert</surname> <given-names>M</given-names></name> <name><surname>Callaway</surname> <given-names>LK</given-names></name> <name><surname>Barrett</surname> <given-names>HL</given-names></name></person-group>. <article-title>Ketones in pregnancy: why is it considered necessary to avoid them and what is the evidence behind their perceived risk?</article-title> <source>Diabetes Care</source>. (<year>2021</year>) <volume>44</volume>:<fpage>280</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.2337/dc20-2008</pub-id>, PMID: <pub-id pub-id-type="pmid">33444162</pub-id></citation></ref>
<ref id="ref129"><label>129.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>D&#x00FC;king</surname> <given-names>T</given-names></name> <name><surname>Spieth</surname> <given-names>L</given-names></name> <name><surname>Berghoff</surname> <given-names>SA</given-names></name> <name><surname>Piepkorn</surname> <given-names>L</given-names></name> <name><surname>Schmidke</surname> <given-names>AM</given-names></name> <name><surname>Mitkovski</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Ketogenic diet uncovers differential metabolic plasticity of brain cells. Science</article-title>. <source>Advances</source>. (<year>2022</year>) <volume>8</volume>:<fpage>eabo7639</fpage>. doi: <pub-id pub-id-type="doi">10.1126/sciadv.abo7639</pub-id>, PMID: <pub-id pub-id-type="pmid">36112685</pub-id></citation></ref>
</ref-list>
</back>
</article>